

RadNet, Inc.
Form 10-Q
May 10, 2013

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

FORM 10-Q

(Mark One)

T **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934**

For the quarterly period ended March 31, 2013

OR

£ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934**

For the transition period from _____ to _____

Commission File Number 0-19019

RadNet, Inc.

(Exact name of registrant as specified in charter)

**Delaware
(State or other jurisdiction of**

**13-3326724
(I.R.S. Employer**

incorporation or organization) Identification No.)

**1510 Cotner Avenue
Los Angeles, California 90025
(Address of principal executive offices) (Zip Code)
(310) 478-7808**

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities and Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer", "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer Accelerated filer Non-accelerated filer Smaller reporting company
(do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act)

Yes No

The number of shares of the registrant's common stock outstanding on May 6, 2013, was 40,089,196 shares.

Table of Contents

RADNET, INC.

INDEX

PART I – FINANCIAL INFORMATION	<u>Page</u>
ITEM 1. Condensed Consolidated Financial Statements (unaudited)	
Condensed Consolidated Balance Sheets at March 31, 2013 and December 31, 2012	3
Condensed Consolidated Statements of Operations for the Three Months ended March 31, 2013 and 2012	4
Condensed Consolidated Statements of Comprehensive Income (Loss) for the Three Months ended March 31, 2013 and 2012	5
Condensed Consolidated Statement of Equity Deficit for the Three Months ended March 31, 2013	6
Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2013 and 2012	7
Notes to Condensed Consolidated Financial Statements	9
ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations	27
ITEM 3. Quantitative and Qualitative Disclosures About Market Risk	37
ITEM 4. Controls and Procedures	39
 PART II – OTHER INFORMATION	
ITEM 1. Legal Proceedings	38
ITEM 1A. Risk Factors	38
ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds	39
ITEM 3. Defaults Upon Senior Securities	39
ITEM 4. Mine Safety Disclosures	39

ITEM 5. Other Information	39
ITEM 6. Exhibits	39
SIGNATURES	40
INDEX TO EXHIBITS	41

PART I - FINANCIAL INFORMATION**RADNET, INC. AND SUBSIDIARIES****CONDENSED CONSOLIDATED BALANCE SHEETS****(IN THOUSANDS EXCEPT SHARE DATA)**

	March 31, 2013 (unaudited)	December 31, 2012
ASSETS		
CURRENT ASSETS		
Cash and cash equivalents	\$ 431	\$ 362
Accounts receivable, net	134,939	129,194
Current portion of deferred tax assets	8,792	7,607
Prepaid expenses and other current assets	20,213	18,737
Total current assets	164,375	155,900
PROPERTY AND EQUIPMENT, NET	217,443	216,560
OTHER ASSETS		
Goodwill	197,090	193,871
Other intangible assets	52,236	51,674
Deferred financing costs	11,387	11,977
Investment in joint ventures	27,959	28,598
Deferred tax assets, net of current portion	53,054	52,790
Deposits and other	3,590	3,749
Total assets	\$ 727,134	\$ 715,119
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)		
CURRENT LIABILITIES		
Accounts payable, accrued expenses and other	\$ 112,808	\$ 105,929
Due to affiliates	1,495	1,602
Deferred revenue	1,276	1,273
Current portion of deferred rent	1,262	1,164
Current portion of notes payable	5,226	4,703
Current portion of obligations under capital leases	3,138	3,942
Total current liabilities	125,205	118,613
LONG-TERM LIABILITIES		
Deferred rent, net of current portion	16,185	15,850
Line of credit	34,500	33,000
Notes payable, net of current portion	537,799	537,009
Obligations under capital lease, net of current portion	3,350	3,753
Other non-current liabilities	8,481	8,895
Total liabilities	725,520	717,120

STOCKHOLDERS' EQUITY (DEFICIT)

Common stock - \$.0001 par value, 200,000,000 shares authorized; 39,889,196, and 38,540,482 shares issued and outstanding at March 31, 2013 and December 31, 2012, respectively	4	4
Paid-in-capital	172,037	168,415
Accumulated other comprehensive income (loss)	(20)	39
Accumulated deficit	(172,435)	(171,093)
Total RadNet, Inc.'s stockholders' equity deficit	(414)	(2,635)
Noncontrolling interests	2,028	634
Total stockholders' equity (deficit)	1,614	(2,001)
Total liabilities and stockholders' equity (deficit)	\$ 727,134	\$ 715,119

The accompanying notes are an integral part of these financial statements.

RADNET, INC. AND SUBSIDIARIES**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS****(IN THOUSANDS EXCEPT SHARE DATA)****(unaudited)**

	Three Months Ended March 31,	
	2013	2012
NET SERVICE FEE REVENUE		
Service fee revenue, net of contractual allowances and discounts	\$ 179,762	\$ 168,500
Provision for bad debts	(6,822) (6,484
Net service fee revenue	172,940	162,016
OPERATING EXPENSES		
Cost of operations	149,562	135,400
Depreciation and amortization	14,760	14,892
Loss on sale and disposal of equipment	170	24
Severance costs	123	449
Total operating expenses	164,615	150,765
INCOME FROM OPERATIONS	8,325	11,251
OTHER EXPENSES		
Interest expense	12,147	13,567
Other income	(2) (1,147
Total other expenses	12,145	12,420
LOSS BEFORE INCOME TAXES AND EQUITY IN EARNINGS OF JOINT VENTURES	(3,820) (1,169
Benefit from (provision for) income taxes	1,248	(245
Equity in earnings of joint ventures	1,206	1,262
NET LOSS	(1,366) (152
Net loss attributable to noncontrolling interests	(24) (41
NET LOSS ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS	\$(1,342) \$(111
BASIC AND DILUTED NET LOSS PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS	\$(0.03) \$(0.00
WEIGHTED AVERAGE SHARES OUTSTANDING		
Basic and diluted	39,314,447	37,669,921

The accompanying notes are an integral part of these financial statements.

RADNET, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(in thousands)

(unaudited)

	Three Months Ended March 31, 2013 2012	
NET LOSS	\$(1,366)	\$(152)
Foreign currency translation adjustments	(59)	6
Reclassification of net cash flow hedge losses included in net loss during the period	–	276
COMPREHENSIVE (LOSS) INCOME	(1,425)	130
Less comprehensive loss attributable to non-controlling interests	(24)	(41)
COMPREHENSIVE (LOSS) INCOME ATTRIBUTIBLE TO RADNET, INC. COMMON STOCKHOLDERS	\$(1,449)	\$89

The accompanying notes are an integral part of these financial statements.

RADNET, INC. AND SUBSIDIARIES**CONDENSED CONSOLIDATED STATEMENT OF EQUITY (DEFICIT)****(IN THOUSANDS EXCEPT SHARE DATA)**

(unaudited)

	Common Stock	Paid-in	Accumulated	Accumulated	Total	RadNet, Inc.	Noncontrolling	Total
	Shares	Amount	Capital	Deficit	Other	Equity	Interests	Equity
					Comprehensive	(Deficit)		(Deficit)
					Loss			
BALANCE - JANUARY 1, 2013	38,540,482	\$ 4	\$ 168,415	\$(171,093)	\$ 39	\$(2,635)	\$ 634	\$(2,001)
Issuance of common stock upon exercise of options/warrants	898,714	–	469	–	–	469	–	469
Stock-based compensation	–	–	952	–	–	952	–	952
Issuance of restricted stock	450,000	–	–	–	–	–	–	–
Sale of a noncontrolling interest in one of our consolidated joint ventures	–	–	2,201	–	–	2,201	439	2,640
Purchase of a controlling interest in a joint venture	–	–	–	–	–	–	979	979
Change in cumulative foreign currency translation adjustment	–	–	–	–	(59)	(59)	–	(59)
Net loss	–	–	–	(1,342)	–	(1,342)	(24)	(1,366)
BALANCE - MARCH 31, 2013	39,889,196	\$ 4	\$ 172,037	\$(172,435)	\$ (20)	\$(414)	\$ 2,028	\$ 1,614

The accompanying notes are an integral part of these financial statements.

RADNET, INC. AND SUBSIDIARIES**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (IN THOUSANDS)****(Unaudited)**

	Three months ended March 31,	
	2013	2012
CASH FLOWS FROM OPERATING ACTIVITIES		
Net loss	\$(1,366)	\$(152)
Adjustments to reconcile net loss to net cash provided by operating activities:		
Depreciation and amortization	14,760	14,892
Provision for bad debt	6,822	6,484
Equity in earnings of joint ventures	(1,206)	(1,262)
Distributions from joint ventures	1,921	1,575
Deferred rent amortization	433	288
Amortization of deferred financing cost	457	602
Amortization of bond and term loan discounts	400	234
Loss on sale and disposal of equipment	170	24
Amortization of cash flow hedge	–	276
Stock-based compensation	952	1,175
Changes in operating assets and liabilities, net of assets acquired and liabilities assumed in purchase transactions:		
Accounts receivable	(11,782)	(12,023)
Other current assets	(5,099)	(683)
Other assets	(105)	(64)
Deferred revenue	3	86
Accounts payable, accrued expenses and other	8,861	3,979
Net cash provided by operating activities	15,221	15,431
CASH FLOWS FROM INVESTING ACTIVITIES		
Purchase of imaging facilities	(3,625)	(580)
Purchase of property and equipment	(12,926)	(13,962)
Proceeds from sale of equipment	270	410
Proceeds from sale of noncontrolling interests	2,640	–
Proceeds from sale of imaging facilities	–	2,300
Purchase of equity interest in joint ventures	(724)	(920)
Net cash used in investing activities	(14,365)	(12,752)
CASH FLOWS FROM FINANCING ACTIVITIES		
Principal payments on notes and leases payable	(2,697)	(4,479)
Proceeds from, net of payments on, line of credit	1,500	2,700
Payments to counterparties of interest rate swaps, net of amounts received	–	(1,500)
Distributions to noncontrolling interests	–	(26)
Proceeds from issuance of common stock upon exercise of options/warrants	469	–
Net cash used in financing activities	(728)	(3,305)
EFFECT OF EXCHANGE RATE CHANGES ON CASH	(59)	5

Edgar Filing: RadNet, Inc. - Form 10-Q

NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	69	(621)
CASH AND CASH EQUIVALENTS, beginning of period	362	2,455
CASH AND CASH EQUIVALENTS, end of period	\$431	\$1,834
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION		
Cash paid during the period for interest	\$5,531	\$6,841

The accompanying notes are an integral part of these financial statements.

7

RADNET, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS (CONTINUED)

(unaudited)

Supplemental Schedule of Non-Cash Investing and Financing Activities

We acquired equipment and certain leasehold improvements for approximately \$7.7 million and \$12.7 million during the three months ended March 31, 2013 and 2012, respectively, that we had not paid for as of March 31, 2013 and 2012, respectively. The offsetting amount due was recorded in our consolidated balance sheet under accounts payable and accrued expenses.

Detail of investing activity related to acquisitions can be found in Note 2.

RADNET, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

NOTE 1 – NATURE OF BUSINESS AND BASIS OF PRESENTATION

At March 31, 2013, we operated directly or indirectly through joint ventures, 248 centers located in California, Maryland, Florida, Delaware, New Jersey, Rhode Island and New York. We provide diagnostic imaging services including magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology, or X-ray, fluoroscopy and other related procedures. Our operations comprise a single segment for financial reporting purposes.

The consolidated financial statements include the accounts of Radnet Management, Inc. (or “Radnet Management”) and Beverly Radiology Medical Group III, a professional partnership (“BRMG”). The consolidated financial statements also include Radnet Management I, Inc., Radnet Management II, Inc., Radiologix, Inc., Radnet Managed Imaging Services, Inc., Delaware Imaging Partners, Inc., New Jersey Imaging Partners, Inc. and Diagnostic Imaging Services, Inc. (“DIS”), all wholly owned subsidiaries of Radnet Management. All of these affiliated entities are referred to collectively as “RadNet”, “we”, “us”, “our” or the “Company” in this report.

Accounting Standards Codification (“ASC”) Section 810-10-15-14 stipulates that generally any entity with a) insufficient equity to finance its activities without additional subordinated financial support provided by any parties, or b) equity holders that, as a group, lack the characteristics specified in the ASC which evidence a controlling financial interest, is considered a Variable Interest Entity (“VIE”). We consolidate all VIEs in which we own a majority voting interest and all VIEs for which we are the primary beneficiary. We determine whether we are the primary beneficiary of a VIE through a qualitative analysis that identifies which variable interest holder has the controlling financial interest in the VIE. The variable interest holder who has both of the following has the controlling financial interest and is the primary beneficiary: (1) the power to direct the activities of the VIE that most significantly impact the VIE’s economic performance and (2) the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE. In performing our analysis, we consider all relevant facts and circumstances, including: the design and activities of the VIE, the terms of the contracts the VIE has entered into, the nature of the VIE’s variable interests issued and how they were negotiated with or marketed to potential investors, and which parties participated significantly in the design or redesign of the entity.

Howard G. Berger, M.D. is our President and Chief Executive Officer, a member of our Board of Directors and is deemed to be the beneficial owner, directly and indirectly, of approximately 13.5% of our outstanding common stock. Dr. Berger also owns, indirectly, 99% of the equity interests in BRMG. BRMG provides all of the professional medical services at the majority of our facilities located in California under a management agreement with us, and

employs physicians or contracts with various other independent physicians and physician groups to provide the professional medical services at most of our other California facilities. We generally obtain professional medical services from BRMG in California, rather than provide such services directly or through subsidiaries, in order to comply with California's prohibition against the corporate practice of medicine. However, as a result of our close relationship with Dr. Berger and BRMG, we believe that we are able to better ensure that medical service is provided at our California facilities in a manner consistent with our needs and expectations and those of our referring physicians, patients and payors than if we obtained these services from unaffiliated physician groups. BRMG is a partnership of ProNet Imaging Medical Group, Inc., Breastlink Medical Group, Inc. and Beverly Radiology Medical Group, Inc., each of which are 99% or 100% owned by Dr. Berger.

John V. Crues III, M.D. is our Medical Director, a member of our Board of Directors and a 1% owner of BRMG. Dr. Crues also owns a controlling interest in three medical groups ("Crues Entities") which provide professional medical services at our imaging facilities located in Manhattan, New York, which we acquired through our December 31, 2012 acquisition of Lenox Hill.

RadNet provides non-medical, technical and administrative services to BRMG and the Crues Entities for which it receives a management fee, per the related management agreements. Through these management agreements and our relationship with both Dr. Berger and Dr. Crues, we have exclusive authority over all non-medical decision making related to the ongoing business operations of BRMG and the Crues Entities. Through our management agreements with BRMG and the Crues Entities, we determine the annual budget of BRMG and the Crues Entities and make all physician employment decisions. BRMG and the Crues Entities both have insignificant operating assets and liabilities, and de minimis equity. Through the management agreements with us, all cash flows of both BRMG and the Crues Entities are transferred to us.

We have determined that BRMG and the Crues Entities are variable interest entities, and that we are the primary beneficiary, and consequently, we consolidate the revenue and expenses of each. BRMG and the Crues Entities combined recognized \$17.4 million and \$12.7 million of revenue, net of management service fees to RadNet, Inc., for the three months ended March 31, 2013 and 2012, respectively, and \$17.4 million and \$12.7 million of operating expenses for the three months ended March 31, 2013 and 2012, respectively. RadNet, Inc. recognized in its condensed consolidated statement of operations \$80.6 million and \$63.1 million of total billed net service fee revenue relating to these entities for the three months ended March 31, 2013 and 2012, respectively, of which \$63.2 million and \$50.4 million was for management services provided to BRMG and the Crues Entities relating primarily to the technical portion of total billed revenue for the three months ended March 31, 2013 and 2012, respectively. The cash flows of BRMG and the Crues Entities are included in the accompanying consolidated statements of cash flows. All intercompany balances and transactions have been eliminated in consolidation. In our consolidated balance sheets at March 31, 2013 and December 31, 2012, we have included approximately \$60.5 million and \$51.8 million, respectively, of accounts receivable and approximately \$8.8 million and \$6.3 million, respectively, of accounts payable and accrued liabilities, related to BRMG and the Crues Entities combined.

The creditors of both BRMG and the Crues Entities do not have recourse to our general credit and there are no other arrangements that could expose us to losses. However, both BRMG and the Crues Entities are managed to recognize no net income or net loss and, therefore, RadNet may be required to provide financial support to cover any operating expenses in excess of operating revenues.

Aside from centers in California and Manhattan, New York where we contract with BRMG and the Crues Entities for the provision of professional medical services, at the remaining centers in California and at all of the centers which are located outside of California except for Manhattan, New York, we have entered into long-term contracts with independent radiology groups in the area to provide physician services at those facilities. These third party radiology practices provide professional services, including supervision and interpretation of diagnostic imaging procedures, in our diagnostic imaging centers. The radiology practices maintain full control over the provision of professional services. The contracted radiology practices generally have outstanding physician and practice credentials and reputations; strong competitive market positions; a broad sub-specialty mix of physicians; a history of growth and potential for continued growth. In these facilities we enter into long-term agreements with radiology practice groups (typically 40 years). Under these arrangements, in addition to obtaining technical fees for the use of our diagnostic imaging equipment and the provision of technical services, we provide management services and receive a fee based on the practice group's professional revenue, including revenue derived outside of our diagnostic imaging centers. We own the diagnostic imaging equipment and, therefore, receive 100% of the technical reimbursements associated with imaging procedures. The radiology practice groups retain the professional reimbursements associated with imaging procedures after deducting management service fees paid to us. We have no financial controlling interest in the independent (non-BRMG) radiology practices; accordingly, we do not consolidate the financial statements of those practices in our consolidated financial statements.

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X and, therefore, do not include all information and footnotes necessary for a fair presentation of financial position, results of operations and cash flows in conformity with U.S. generally accepted accounting principles complete financial statements; however, in the opinion of our management, all adjustments consisting of normal recurring adjustments necessary for a fair presentation of the financial position, results of operations and cash flows for the interim periods ended March 31, 2013 and 2012 have

been made. The results of operations for any interim period are not necessarily indicative of the results for a full year. These interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes thereto contained in our annual report on Form 10-K for the year ended December 31, 2012 as amended.

Significant Accounting Policies

As of the period covered in this report, there have been no material changes to the significant accounting policies we use, and have explained, in our annual report on Form 10-K for the fiscal year ended December 31, 2012 as amended.

Revenues

Service fee revenue, net of contractual allowances and discounts, consists of net patient fees received from various payers and patients themselves based mainly upon established contractual billing rates, less allowances for contractual adjustments. As it relates to BRMG centers, this service fee revenue includes payments for both the professional medical interpretation revenue recognized by BRMG as well as the payment for all other aspects related to our providing the imaging services, for which we earn management fees from BRMG. As it relates to non-BRMG centers, this service fee revenue is earned through providing the administration of the non-medical functions relating to the professional medical practice at our non-BRMG centers, including among other functions, provision of clerical and administrative personnel, bookkeeping and accounting services, billing and collection, provision of medical and office supplies, secretarial, reception and transcription services, maintenance of medical records, and advertising, marketing and promotional activities.

Service fee revenues are recorded during the period the patient services are provided based upon the estimated amounts due from the patients and third-party payers. Third-party payers include federal and state agencies (under the Medicare and Medicaid programs), managed care health plans, commercial insurance companies and employers. Estimates of contractual allowances under managed care health plans are based upon the payment terms specified in the related contractual agreements. Contractual payment terms in managed care agreements are generally based upon predetermined rates per discounted fee-for-service rates. We also record a provision for doubtful accounts (based primarily on historical collection experience) related to patients and copayment and deductible amounts for patients who have health care coverage under one of our third-party payers.

Our service fee revenue, net of contractual allowances and discounts less the provision for bad debts for the three months ended March 31, are summarized in the following table (in thousands):

	2013	2012
Commercial Insurance	\$97,685	\$91,745
Managed Care Capitated Payors	22,583	21,626
Medicare	35,713	34,077
Medicaid	5,777	5,570
Other	18,004	15,483
Service fee revenue, net of contractual allowances and discounts	179,762	168,500
Provision for bad debts	(6,822)	(6,484)
Net service fee revenue	\$172,940	\$162,016

The break-out of our service fee revenue, net of contractual allowances and discounts, is calculated based upon global payments received from consolidated imaging centers from dates of service during each respective period illustrated.

Provision for Bad Debts

Although outcomes vary, our policy is to attempt to collect amounts due from patients, including co-payments and deductibles due from patients with insurance, at the time of service. We provide for an allowance against accounts receivable that could become uncollectible by establishing an allowance to reduce the carrying value of such receivables to their estimated net realizable value. We estimate this allowance based on the aging of our accounts receivable by each type of payer over an 18-month look-back period, and other relevant factors. A significant portion of our provision for bad debt relates to co-payments and deductibles owed to us by patients with insurance. There are various factors that can impact collection trends, such as changes in the economy, which in turn have an impact on the increased burden of co-payments and deductibles to be made by patients with insurance. These factors continuously change and can have an impact on collection trends and our estimation process.

Deferred Tax Assets

Income tax expense is computed using an asset and liability method and using expected annual effective tax rates. Under this method, deferred income tax assets and liabilities result from temporary differences in the financial reporting bases and the income tax reporting bases of assets and liabilities. The measurement of deferred tax assets is reduced, if necessary, by the amount of any tax benefit that, based on available evidence, is not expected to be realized. When it appears more likely than not that deferred taxes will not be realized, a valuation allowance is recorded to reduce the deferred tax asset to its estimated realizable value. For net deferred tax assets we consider estimates of future taxable income, including tax planning strategies, in determining whether our net deferred tax assets are more likely than not to be realized.

Liquidity and Capital Resources

We had cash and cash equivalents of \$431,000 and accounts receivable of \$134.9 million at March 31, 2013, compared to cash and cash equivalents of \$362,000 and accounts receivable of \$129.2 million at December 31, 2012. We had a working capital balance of \$39.2 million and \$37.3 million at March 31, 2013 and December 31, 2012, respectively. We had a net loss attributable to RadNet, Inc. common stockholders for the three months ended March 31, 2013 and 2012 of \$1.3 million and \$111,000, respectively. We also had a stockholders' equity (deficit) of \$1.6 million and (\$2.0 million) at March 31, 2013 and December 31, 2012, respectively.

We operate in a capital intensive, high fixed-cost industry that requires significant amounts of capital to fund operations. In addition to operations, we require a significant amount of capital for the initial start-up and development of new diagnostic imaging facilities, the acquisition of additional facilities and new diagnostic imaging equipment. Because our cash flows from operations have been insufficient to fund all of these capital requirements, we have depended on the availability of financing under credit arrangements with third parties.

Based on our current level of operations, we believe that cash flow from operations and available cash, together with available borrowings from our senior secured credit facilities, will be adequate to meet our short-term and long-term liquidity needs. Our future liquidity requirements will be for working capital, capital expenditures, debt service and general corporate purposes. Our ability to meet our working capital and debt service requirements, however, is subject to future economic conditions and to financial, business and other factors, many of which are beyond our control. If we are not able to meet such requirements, we may be required to seek additional financing. There can be no assurance that we will be able to obtain financing from other sources on terms acceptable to us, if at all.

On a continuing basis, we also consider various transactions to increase shareholder value and enhance our business results, including acquisitions, divestitures and joint ventures. These types of transactions may result in future cash proceeds or payments but the general timing, size or success of any acquisition, divestiture or joint venture effort and the related potential capital commitments cannot be predicted. We expect to fund any future acquisitions primarily with cash flow from operations and borrowings, including borrowing from amounts available under our senior secured credit facilities or through new equity or debt issuances.

We and our subsidiaries or affiliates may from time to time, in our or their sole discretion, purchase, repay, redeem or retire any of our outstanding debt or equity securities in privately negotiated or open market transactions, by tender offer or otherwise. However, we have no formal plan of doing so at this time.

Included in our condensed consolidated balance sheet at March 31, 2013 are \$198.1 million of senior notes (net of unamortized discounts of \$1.9 million), \$341.1 million of senior secured term loan debt (net of unamortized discounts of \$7.2 million) and \$34.5 million aggregate principal amount outstanding under the revolving credit facility.

Accordingly, the par values outstanding of our senior notes and senior secured term loan are \$200 million and \$348.25 million, respectively.

The following describes our most recent financing activities:

2010 Credit Agreement

On April 6, 2010, we completed a series of transactions which we refer to as our “debt refinancing plan” for an aggregate of \$585.0 million. As part of the debt refinancing plan, our wholly owned subsidiary, Radnet Management, Inc., issued and sold \$200.0 million in 10 3/8% senior unsecured notes due 2018 (the “senior notes”). All payments of the senior notes, including principal and interest, are guaranteed jointly and severally on a senior unsecured basis by RadNet, Inc. and all of Radnet Management’s current and future domestic wholly owned restricted subsidiaries. The senior notes were issued under an indenture agreement dated April 6, 2010 (the “Indenture”), by and among Radnet Management, as issuer, RadNet, Inc., as parent guarantor, the subsidiary guarantors thereof and U.S. Bank National Association, as trustee, in a private placement that was not subject to the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”). The senior notes initially issued on April 6, 2010 in a private placement were subsequently publicly offered for exchange enabling holders of the outstanding senior notes to exchange the outstanding notes for publicly registered exchange notes with nearly identical terms. The exchange offer was completed on February 14, 2011.

In addition to the issuance of senior notes, Radnet Management entered into a Credit and Guaranty Agreement with a syndicate of lenders (the “Credit Agreement”), whereby Radnet Management obtained \$385.0 million in senior secured first-lien bank financing, consisting of (i) a \$285.0 million, six-year term loan facility and (ii) a \$100.0 million, five-year revolving credit facility, including a swing line subfacility and a letter of credit subfacility (collectively, the “Credit Facilities”).

Radnet Management’s obligations under the Credit Agreement were unconditionally guaranteed by RadNet, Inc., all of Radnet Management’s current and future domestic subsidiaries as well as certain affiliates, including Beverly Radiology Medical Group III and its equity holders (Beverly Radiology Medical Group, Inc., BreastLink Medical Group, Inc. and ProNet Imaging Medical Group, Inc.). The Credit Facilities created by the Credit Agreement were secured by a perfected first-priority security interest in all of Radnet Management’s and the guarantors’ tangible and intangible assets, including, but not limited to, pledges of equity interests of Radnet Management and all of our current and future domestic subsidiaries.

2012 Refinancing

On October 10, 2012 we completed the refinancing of the Credit Facilities by entering into a new Credit and Guaranty Agreement with a syndicate of banks and other financial institutions (the "Refinance Agreement"). The total amount of refinancing was \$451.25 million, consisting of (i) a \$350 million senior secured term loan and (ii) a \$101.25 million senior secured revolving credit facility. The obligations of Radnet Management, Inc. under the Refinance Agreement are guaranteed by RadNet, Inc. and all of Radnet Management's current and future domestic subsidiaries and certain of our affiliates. The obligations under the Refinance Agreement, including the guarantees, are secured by a perfected first-priority security interest in all of Radnet Management's and the guarantors' tangible and intangible assets, including, but not limited to, pledges of equity interests of Radnet Management and all of our current and future domestic subsidiaries.

The termination date for the \$350 million term loan is the earliest to occur of (i) the sixth anniversary of the closing date (October 10, 2012), (ii) the date on which all of the term loans shall become due and payable in full under the Refinance Agreement whether by acceleration or otherwise and (iii) October 1, 2017 if our senior notes due 2018 have not been refinanced by such date. The termination date for the \$101.25 million revolving credit facility is the earliest to occur of (i) the fifth anniversary of the closing date, (ii) the date the revolving credit facility is permanently reduced to zero pursuant to section 2.13(b) of the Refinance Agreement, (iii) the date of the termination of the revolving credit facility pursuant to section 8.01 of the Refinance Agreement and (iv) October 1, 2017 if our senior notes due 2018 have not been refinanced by such date.

In connection with the refinancing of the Credit Facilities in 2012, Radnet Management used the net proceeds to repay in full its existing six year term loan facility for \$277.9 million in principal amount outstanding, which would have matured on April 6, 2016, and its revolving credit facility for \$59.8 million in principal amount outstanding, which would have matured on April 6, 2015.

Refinance Agreement

Interest. The Refinance Agreement bears interest through maturity at a rate determined by adding the applicable margin to either (a) the Base Rate, which is defined in the Refinance Agreement as the highest of (i) the prime rate quoted in the Wall Street Journal, (ii) the rate which is 0.5% in excess of the federal funds rate, (iii) (with respect to term loans only) 2.25% and (iv) 1.00% in excess of the one-month Adjusted Eurodollar Rate at such time, or (b) the Adjusted Eurodollar Rate, which is defined in the Refinance Agreement as the higher of (i) the London interbank offered rate, adjusted for statutory reserve requirements, for the respective interest period, as determined by the administrative agent and (ii) (with respect to term loans only) 1.25%. As used in the Refinance Agreement, applicable margin means (i) (a) with respect to term loans that are Eurodollar Rate Loans, 4.25% per annum and (b) with respect to term loans that are Base Rate Loans, 3.25% per annum; and (ii) (a) with respect to revolving loans that are Eurodollar Rate Loans, 4.25% per annum and (b) with respect to revolving loans and swing line loans that are Base Rate Loans, 3.25% per annum.

Payments. Commencing on December 31, 2012 we began making quarterly amortization payments on the term loan facility under the Refinance Agreement, each in the amount of \$875,000, with the remaining principal balance paid at maturity. Under the Refinance Agreement, we are also required to make mandatory prepayments, subject to specified exceptions, from consolidated excess cash flow, and upon certain events, including, but not limited to, (i) the receipt of net cash proceeds from the sale or other disposition of any property or assets by us or any of our subsidiaries, (ii) the receipt of net cash proceeds from insurance or condemnation proceeds paid on account of any loss of any property or assets of us or any of our subsidiaries, and (iii) the receipt of net cash proceeds from the incurrence of indebtedness by us or any of our subsidiaries (other than certain indebtedness otherwise permitted under the Refinance Agreement).

Guarantees and Collateral. The obligations under the Refinance Agreement are guaranteed by us, all of our current and future domestic subsidiaries and certain of our affiliates. The obligations under the Refinance Agreement and the guarantees are secured by a perfected first priority security interest in all of Radnet Management's and the guarantors' tangible and intangible assets, including, but not limited to, pledges of equity interests of Radnet Management and all of our current and future domestic subsidiaries.

Restrictive Covenants. In addition to certain customary covenants, the Refinance Agreement places limits on our ability to declare dividends or redeem or repurchase capital stock, prepay, redeem or purchase debt, incur liens and engage in sale-leaseback transactions, make loans and investments, incur additional indebtedness, amend or otherwise alter debt and other material agreements, engage in mergers, acquisitions and asset sales, enter into transactions with affiliates and alter the business we and our subsidiaries currently conduct.

Financial Covenants. The Refinance Agreement contains financial covenants including a maximum total leverage ratio and a limit on annual capital expenditures.

Events of Default. In addition to certain customary events of default, events of default under the Refinance Agreement include failure to pay principal or interest when due, a material breach of any representation or warranty contained in the loan documents, covenant defaults, events of bankruptcy and a change of control. The occurrence of an event of default could permit the lenders under the Refinance Agreement to declare all amounts borrowed, together with accrued interest and fees, to be immediately due and payable and to exercise other default remedies.

2013 Amendment to the Refinance Agreement

On April 3, 2013, we entered into a first amendment to the Refinance Agreement. Pursuant to this amendment, we re-priced our current senior secured term loans and borrowed an additional \$40.0 million under the senior secured loan facility.

Pursuant to the amendment to the Refinance Agreement, the interest rate spread over LIBOR for the senior secured term loans has been reduced from 4.25% to 3.25% and the interest rate spread over the alternative base rate for the senior secured term loans has been reduced from 3.25% to 2.25%. The minimum LIBOR rate underlying the senior secured term loans has been reduced from 1.25% to 1.0%.

The other material terms of Refinance Agreement remain unchanged and are described immediately above this section under the heading “2012 Refinancing.”

Senior Notes

On April 6, 2010, we issued \$200 million in aggregate amount of unsecured senior notes which have a coupon of 10.375% and were issued at a price of 98.680%. The senior notes were issued by Radnet Management, Inc. and guaranteed jointly and severally on a senior unsecured basis by us and all of our current and future wholly-owned domestic restricted subsidiaries. The senior notes were offered and sold in a private placement exempt from registration under the Securities Act to qualified institutional buyers pursuant to Rule 144A and Regulation S under the Securities Act. We pay interest on the senior notes on April 1 and October 1, commencing October 1, 2010, and they will expire on April 1, 2018. The senior notes are governed under the Indenture. Under the terms of the Indenture, we agreed to file a registration statement with the SEC relating to an offer to exchange the senior notes for registered publicly tradable notes that have substantially identical terms as the senior notes. On August 30, 2010, we filed a registration statement on Form S-4 with the SEC relating to the offer to exchange the senior notes. On January 13, 2011, our registration statement was declared effective by the SEC. On February 14, 2011, we completed an exchange offer whereby all senior notes were exchanged for registered publicly tradable notes.

Ranking. The senior notes and the guarantees:

- rank equally in right of payment with any existing and future unsecured senior indebtedness of the guarantors;
 - rank senior in right of payment to all existing and future subordinated indebtedness of the guarantors;
- are effectively subordinated in right of payment to any secured indebtedness of the guarantors (including indebtedness under the Refinance Agreement) to the extent of the value of the assets securing such indebtedness; and are structurally subordinated in right of payment to all existing and future indebtedness and other liabilities of any of the Company's subsidiaries that is not a guarantor of the senior notes.

Optional Redemption. Radnet Management may redeem the senior notes, in whole or in part, at any time on or after April 1, 2014, at the redemption prices specified under the Indenture. Prior to April 1, 2013, Radnet Management may redeem up to 35% of aggregate principal amount of the senior notes issued under the Indenture from the net proceeds of one or more equity offerings at a redemption price equal to 110.375% of the senior notes redeemed, plus accrued and unpaid interest, if any. Radnet Management is also permitted to redeem the senior notes prior to April 1, 2014, in whole or in part, at a redemption price equal to 100% of the principal amount redeemed, plus a make-whole premium and accrued and unpaid interest, if any.

Change of Control and Asset Sales. If a change in control of Radnet Management occurs, Radnet Management must give holders of the senior notes the opportunity to sell their senior notes at 101% of their face amount, plus accrued interest. If we or one of our restricted subsidiaries sells assets under certain circumstances, Radnet Management will be required to make an offer to purchase the senior notes at their face amount, plus accrued and unpaid interest to the purchase date.

Restrictive Covenants. The Indenture contains covenants that limit, among other things, the ability of us and our restricted subsidiaries, to:

- pay dividends or make certain other restricted payments or investments;
- incur additional indebtedness and issue preferred stock;
- create liens (other than permitted liens) securing indebtedness or trade payables unless the notes are secured on an equal and ratable basis with the obligations so secured, and, if such liens secure subordinated indebtedness, the notes are secured by a lien senior to such liens;
- sell certain assets or merge with or into other companies or otherwise dispose of all or substantially all of our assets;
- enter into certain transactions with affiliates;
- create restrictions on dividends or other payments by our restricted subsidiaries; and
- create guarantees of indebtedness by restricted subsidiaries.

However, these limitations are subject to a number of important qualifications and exceptions, as described in the Indenture. As of March 31, 2013, we were in compliance with all covenants.

NOTE 2 – FACILITY ACQUISITIONS & DISPOSITIONS

On February 28, 2013, we completed our acquisition of a multi-modality imaging center located in Brooklyn, New York by exercising a \$1.00 purchase option to acquire an initial 50% interest (we acquired this option through our December 31, 2012 acquisition of Lenox Hill Radiology which we valued at approximately \$2.5 million) and then by purchasing the remaining 50% interest from the existing partner for approximately \$2.4 million in cash. We have made a fair value determination of the acquired assets and assumed liabilities and approximately \$813,000 of fixed assets, \$4.2 million of goodwill and \$124,000 of notes payable was recorded with respect to this transaction.

On February 8, 2013, we completed the acquisition of a multi modality imaging center located in Manhattan, New York for \$1.0 million. The facility provides MRI, CT, mammography, ultrasound and X-ray services. We have made a fair value determination of the acquired assets and assumed liabilities and approximately \$1.0 million of fixed assets was recorded with respect to this transaction.

On February 5, 2013, we sold a 10% interest in a wholly owned limited liability company consisting of two multi-modality imaging centers located in Bel Air, Maryland for approximately \$2.6 million. On the date of sale, we

recorded approximately \$439,000 of non-controlling interests and \$2.2 million of additional paid in capital with respect to this transaction.

On January 30, 2013, we purchased for \$430,000 an additional 20.9% interest in a joint venture multi-modality imaging center located in Manhattan, New York of which we initially held a 31.5% interest from our December 31, 2012 acquisition of Lenox Hill Radiology which we valued at approximately \$648,000. This additional 20.9% interest gave us a 52.4% controlling interest and so accordingly, we began consolidating this imaging center, recording all of its assets and liabilities at their fair value at January 30, 2013. We have made a fair value determination of the acquired assets and assumed liabilities and approximately \$358,000 of working capital, \$2.1 million of fixed assets, \$2.0 million of goodwill, \$2.4 million of notes payable and \$979,000 of non-controlling interests was recorded with respect to this transaction.

On January 1, 2013, we completed our acquisition of a breast surgery practice located in Mission Viejo, California for \$350,000. We have made a fair value determination of the acquired assets and assumed liabilities and approximately \$135,000 of working capital, \$30,000 of fixed assets and \$185,000 of goodwill was recorded with respect to this transaction.

On December 31, 2012, we completed our acquisition of Lenox Hill Radiology, consisting of three multi-modality imaging centers as well as three additional x-ray facilities all located in Manhattan, New York. We also acquired in this transaction a 31.5% interest in a joint venture multi-modality imaging center in Manhattan, New York and an option to purchase a 50% interest in a multi-modality imaging center located in Brooklyn, New York for \$1.00. The purchase price consisted of approximately \$28.4 million in cash. With the services of an external valuation expert, we have made a final fair value determination of the acquired assets and assumed liabilities and \$4.5 million of working capital, \$8.7 million of fixed assets, which is approximately \$1.5 million higher than our initial estimate, \$648,000 of joint venture interests, \$2.5 million in a \$1.00 joint venture purchase option, \$100,000 of intangible assets, \$14.0 million of goodwill and indefinite life intangibles which is approximately \$1.3 million lower than our initial estimate, the assumption of approximately \$650,000 of other liabilities, which is approximately \$150,000 higher than our initial estimate, and \$1.3 million of capital lease debt was recorded with respect to this transaction.

NOTE 3 – RECENT ACCOUNTING STANDARDS

Reclassifications Out of Accumulated Other Comprehensive Income. In February 2013, the Financial Accounting Standards Board (FASB) issued guidance for the reporting of amounts reclassified out of accumulated other comprehensive income. The new guidance requires entities to report the effect of significant reclassifications out of accumulated other comprehensive income on the respective line items in net income if the amount being reclassified is required under U.S. generally accepted accounting principles (GAAP) to be reclassified in its entirety to net income. The new guidance does not change the current requirements for reporting net income or other comprehensive income in financial statements and is effective prospectively for reporting periods beginning after December 15, 2012. The adoption of this new guidance in 2013 did not impact our financial position, results of operations or cash flows.

Balance Sheet Offsetting. In December 2012, the FASB issued guidance for new disclosure requirements related to the nature of an entity's rights of set-off and related arrangements associated with its financial instruments and derivative instruments. The new guidance is effective for annual reporting periods, and interim periods within those years, beginning on or after January 1, 2013. The adoption of this new guidance in 2013 did not impact our financial position, results of operations or cash flows.

NOTE 4 – EARNINGS PER SHARE

Earnings per share is based upon the weighted average number of shares of common stock and common stock equivalents outstanding, net of common stock held in treasury, as follows (in thousands except share and per share data):

	Three Months Ended March 31,	
	2013	2012
Net loss attributable to RadNet, Inc.'s common stockholders	\$(1,342) \$(111
BASIC AND DILUTED NET LOSS PER SHARE ATTRIBUTABLE TO RADNET, INC.'S COMMON STOCKHOLDERS		
Weighted average number of common shares outstanding during the period	39,314,447	37,669,921
Basic and diluted net loss per share attributable to RadNet, Inc.'s common stockholders	\$(0.03) \$(0.00

For the three months ended March 31, 2013 and 2012, we excluded all options and warrants in the calculation of diluted loss per share because their effect is anti-dilutive.

NOTE 5 – INVESTMENT IN JOINT VENTURES

We have eight unconsolidated joint ventures with ownership interests ranging from 35% to 50%. These joint ventures represent partnerships with hospitals, health systems or radiology practices and were formed for the purpose of owning and operating diagnostic imaging centers. Professional services at the joint venture diagnostic imaging centers are performed by contracted radiology practices or a radiology practice that participates in the joint venture. Our investment in these joint ventures is accounted for under the equity method. Investment in joint ventures decreased approximately \$639,000 to \$28.0 million at March 31, 2013 compared to \$28.6 million at December 31, 2012. This decrease is primarily related to our purchase of a controlling interest in one of these investments resulting in our reclassification of approximately \$648,000 out of this balance as we now consolidate this imaging center business (see Note 2 above for more details regarding this transaction). Additionally, during the three months ended March 31, 2013 we recorded equity earnings of approximately \$1.2 million, made additional equity contributions of \$724,000 and received our respective share of distributions of \$1.9 million.

We received management service fees from the centers underlying these joint ventures of approximately \$2.0 million and \$1.9 million for the three months ended March 31, 2013 and 2012, respectively, and eliminated the uncollected portion of the fees earned associated with our ownership from our net revenue with an offsetting increase to our equity earnings.

The following table is a summary of key financial data for these joint ventures as of March 31, 2013 and for the three months ended March 31, 2013 and 2012 (in thousands):

Balance Sheet Data:	March 31, 2013	
Current assets	\$15,277	
Noncurrent assets	44,169	
Current liabilities	(5,537)
Noncurrent liabilities	(5,871)
Total net assets	\$48,038	
Book value of Radnet joint venture interests	\$22,422	
Cost in excess of book value of acquired joint venture interests	5,232	
Elimination of intercompany profit remaining on Radnet's consolidated balance sheet	305	
Total value of Radnet joint venture interests	\$27,959	
Total book value of other joint venture partner interests	\$25,616	
Income Statement Data for the three months ended March 31,	2013	2012
Net revenue	\$22,281	\$21,076
Net income	\$2,733	\$2,533

NOTE 6 – STOCK-BASED COMPENSATION

Options and Warrants

We have two long-term incentive plans which we refer to as the 2000 Plan and the 2006 Plan. The 2000 Plan was terminated as to future grants when the 2006 Plan was approved by the stockholders in 2006. As of March 31, 2013, we have reserved for issuance under the 2006 Plan 11,000,000 shares of common stock. Certain options granted under the 2006 Plan to employees are intended to qualify as incentive stock options under existing tax regulations. In addition, we may issue non-qualified stock options and warrants under the 2006 Plan from time to time to non-employees, in connection with acquisitions and for other purposes and we may also issue restricted stock under the 2006 Plan. Stock options and warrants generally vest over two to five years and expire five to ten years from date of grant.

As of March 31, 2013, 5,481,250, or approximately 89.4%, of the 6,131,250 outstanding stock options and warrants granted under our option plans are fully vested. During the three months ended March 31, 2013, we did not grant options or warrants under the 2006 Plan.

We have issued warrants outside the 2006 Plan under various types of arrangements to employees, and in exchange for outside services. All warrants issued to employees or consultants after our February 2007 listing on the NASDAQ Global Market have been characterized as awards under the 2006 Plan. All warrants outside the 2006 Plan have been issued with an exercise price equal to the fair value of the underlying common stock on the date of grant. The warrants expire from five to seven years from the date of grant. Vesting terms are determined by the board of directors or the compensation committee of the board of directors at the date of grant.

As of March 31, 2013, 330,000, or 100%, of all the outstanding warrants outside the 2006 Plan are fully vested. During the three months ended March 31, 2013, we did not grant warrants outside of our 2006 Plan.

The following summarizes all of our option and warrant transactions in 2013:

Outstanding Options and Warrants		Weighted Average Exercise price Per Common Share	Weighted Average Remaining Contractual Life (in years)	Aggregate Intrinsic Value
Under the 2006 Plan and 2000 Plan	Shares	Share		
Balance, December 31, 2012	6,231,250	\$ 3.58		
Granted	—	—		
Exercised	—	—		
Canceled or expired	(100,000)	9.23		
Balance, March 31, 2013	6,131,250	3.49	1.67	\$1,392,200
Exercisable at March 31, 2013	5,481,250	3.52	1.54	1,292,317

Non-Plan Outstanding Warrants		Weighted Average Exercise price Per Common Share	Weighted Average Remaining Contractual Life (in years)	Aggregate Intrinsic Value
Balance, December 31, 2012	1,502,898	\$ 1.50		
Granted	—	—		
Exercised	(1,172,898)	1.12		
Canceled or expired	—	—		
Balance, March 31, 2013	330,000	2.87	1.85	\$ 36,000
Exercisable at March 31, 2013	330,000	2.87	1.85	36,000

The aggregate intrinsic value in the table above represents the total pretax intrinsic value (the difference between our closing stock price on March 31, 2013 and the exercise price, multiplied by the number of in-the-money options or warrants, as applicable) that would have been received by the holder had all holders exercised their options or warrants, as applicable, on March 31, 2013. Total intrinsic value of options and warrants exercised during the three months ended March 31, 2013 and 2012 was approximately \$2.3 million and \$265,000, respectively. As of March 31, 2013, total unrecognized stock-based compensation expense related to non-vested employee awards was approximately \$668,000, which is expected to be recognized over a weighted average period of approximately 1.0 year.

Restricted Stock Awards

The 2006 Plan permits the award of restricted stock. On January 2, 2013, we granted awards for 450,000 shares of our common stock to certain employees. Of the awards granted, 170,000 were vested on the award date, 140,000 cliff vest

after one year provided that the employees remain continuously employed through the vesting date and 140,000 cliff vest after two years provided that the employees remain continuously employed through the vesting date. We valued the awards based on the closing market price of our stock on January 2, 2013 which was \$2.51 per share.

At March 31, 2013, the total unrecognized fair value of all restricted stock awards was approximately \$1.4 million, which will be recognized over the remaining vesting period of 2.0 years.

In sum, of the 11,000,000 shares of common stock reserved for issuance under the 2006 Plan, at March 31, 2013, we had 7,563,750 options, warrants and shares of restricted stock outstanding and 3,416,250 available for grant.

NOTE 7 – FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS – Assets and liabilities subject to fair value measurements are required to be disclosed within a fair value hierarchy. The fair value hierarchy ranks the quality and reliability of inputs used to determine fair value. Accordingly, assets and liabilities carried at, or permitted to be carried at, fair value are classified within the fair value hierarchy in one of the following categories based on the lowest level input that is significant to a fair value measurement:

Level 1—Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.

Level 2—Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models such as interest rates and yield curves that can be corroborated by observable market data.

Level 3—Fair value is determined by using inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgment.

The table below summarizes the estimated fair value and carrying amount of our long-term debt as follows (in thousands):

	As of March 31, 2013				
	Level 1	Level 2	Level 3	Total Fair Value	Total Carrying Value
Senior Secured Term Loan	–	351,733	–	351,733	348,250
Senior Notes	–	209,000	–	209,000	200,000

	As of December 31, 2012				
	Level 1	Level 2	Level 3	Total Fair Value	Total Carrying Value
Senior Secured Term Loan	\$–	\$352,180	\$–	\$352,180	\$349,125
Senior Notes	–	204,500	–	204,500	200,000

The carrying value of our line of credit at March 31, 2013 and December 31, 2012 of \$34.5 million and \$33.0 million, respectively, approximated its fair value.

We consider the carrying amounts of cash and cash equivalents, receivables, other current assets and current liabilities to approximate their fair value because of the relatively short period of time between the origination of these instruments and their expected realization or payment. Additionally, we consider the carrying amount of our capital lease obligations to approximate their fair value because the weighted average interest rate used to formulate the carrying amounts approximates current market rates.

NOTE 8 — SUPPLEMENTAL GUARANTOR INFORMATION

In accordance with SEC Regulation S-X, Rule 3-10, Paragraph (d), the following tables present unaudited interim condensed consolidating financial information for: (a) RadNet, Inc. (the “Parent”) on a stand-alone basis as a guarantor of the registered senior notes due 2018 ; (b) Radnet Management, Inc., the subsidiary borrower and issuer (the “Subsidiary Issuer”) of the registered senior notes due 2018; (c) on a combined basis, the guarantor subsidiaries (the “Guarantor Subsidiaries”) of the registered senior notes due 2018, which include all other 100% owned subsidiaries of the Subsidiary Issuer; (d) on a combined basis, the non-guarantor subsidiaries, which include joint venture partnerships of which the Subsidiary Issuer holds investments of 50% or greater, as well as BRMG and the Crues Entities, which we consolidate as VIEs. Separate financial statements of the Subsidiary Issuer or the Guarantor Subsidiaries are not presented because the guarantee by the Parent and each Guarantor Subsidiary is full and unconditional, joint and several.

RADNET, INC. AND SUBSIDIARIES**CONDENSED CONSOLIDATED BALANCE SHEET****March 31, 2013****(in thousands)****(unaudited)**

	Parent	Subsidiary Issuer	Guarantor Subsidiary	Non-Guarantor Subsidiaries	Eliminations	Consolidated
ASSETS						
CURRENT ASSETS						
Cash and cash equivalents	\$—	\$—	\$ 431	\$ —	\$ —	\$ 431
Accounts receivable, net	—	—	64,597	70,342	—	134,939
Current deferred tax assets	—	—	8,792	—	—	8,792
Prepaid expenses and other current assets	—	13,382	6,097	734	—	20,213
Total current assets	—	13,382	79,917	71,076	—	164,375
PROPERTY AND EQUIPMENT, NET	—	49,203	161,970	6,270	—	217,443
OTHER ASSETS						
Goodwill	—	49,139	143,211	4,740	—	197,090
Other intangible assets	—	160	51,974	102	—	52,236
Deferred financing costs, net	—	11,387	—	—	—	11,387
Investment in subsidiaries	(414)	350,608	14,746	—	(364,940)	—
Investment in joint ventures	—	—	27,959	—	—	27,959
Deferred tax assets, net of current portion	—	—	53,054	—	—	53,054
Deposits and other	—	1,596	1,935	59	—	3,590
Total assets	\$ (414)	\$ 475,475	\$ 534,766	\$ 82,247	\$ (364,940)	\$ 727,134
LIABILITIES AND EQUITY (DEFICIT)						
CURRENT LIABILITIES						
Intercompany	\$—	\$(165,623)	\$ 112,383	\$ 53,240	\$ —	\$ —
Accounts payable, accrued expenses and other	—	56,129	48,361	8,318	—	112,808
Due to affiliates	—	—	1,495	—	—	1,495
Deferred revenue	—	—	1,276	—	—	1,276
Current portion of deferred rent	—	605	611	46	—	1,262
Current portion of notes payable	—	3,500	1,004	722	—	5,226
Current portion of obligations under capital leases	—	947	1,301	890	—	3,138
Total current liabilities	—	(104,442)	166,431	63,216	—	125,205
LONG-TERM LIABILITIES						
Deferred rent, net of current portion	—	9,703	6,290	192	—	16,185

Edgar Filing: RadNet, Inc. - Form 10-Q

Line of credit	–	34,500	–	–	–	34,500
Notes payable, net of current portion	–	535,640	638	1,521	–	537,799
Obligations under capital leases, net of current portion	–	488	2,318	544	–	3,350
Other non-current liabilities	–	–	8,481	–	–	8,481
Total liabilities	–	475,889	184,158	65,473	–	725,520
EQUITY (DEFICIT)						
Total Radnet, Inc.'s equity (deficit)	(414)	(414)	350,608	14,746	(364,940)	(414)
Noncontrolling interests	–	–	–	2,028	–	2,028
Total equity (deficit)	(414)	(414)	350,608	16,774	(364,940)	1,614
Total liabilities and equity (deficit)	\$ (414)	\$ 475,475	\$ 534,766	\$ 82,247	\$ (364,940)	\$ 727,134

RADNET, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEET

December 31, 2012

(in thousands)

	Parent	Subsidiary Issuer	Guarantor Subsidiaries	Non-Guarantor Subsidiaries	Eliminations	Consolidated
ASSETS						
CURRENT ASSETS						
Cash and cash equivalents	\$-	\$362	\$-	\$-	\$-	\$362
Accounts receivable, net	-	-	76,838	52,356	-	129,194
Current portion of deferred tax assets	-	-	7,607	-	-	7,607
Prepaid expenses and other current assets	-	9,735	8,308	694	-	18,737
Total current assets	-	10,097	92,753	53,050	-	155,900
PROPERTY AND EQUIPMENT, NET	-	48,025	168,401	134	-	216,560
OTHER ASSETS						
Goodwill	-	48,954	144,072	845	-	193,871
Other intangible assets	-	170	51,394	110	-	51,674
Deferred financing costs	-	11,977	-	-	-	11,977
Investment in subsidiaries	(2,635)	342,796	9,217	-	(349,378)	-
Investment in joint ventures	-	-	28,598	-	-	28,598
Deferred tax assets, net of current portion	-	-	52,790	-	-	52,790
Deposits and other	-	1,821	1,928	-	-	3,749
Total assets	\$(2,635)	\$463,840	\$549,153	\$54,139	\$(349,378)	\$715,119
LIABILITIES AND EQUITY						
DEFICIT						
CURRENT LIABILITIES						
Intercompany	\$-	\$(176,217)	\$138,223	\$37,994	\$-	\$-
Accounts payable, accrued expenses and other	-	57,939	41,696	6,294	-	105,929
Due to affiliates	-	-	1,602	-	-	1,602
Deferred revenue	-	-	1,273	-	-	1,273
Current portion of deferred rent	-	574	590	-	-	1,164
Current portion of notes payable	-	3,500	1,203	-	-	4,703
Current portion of obligations under capital leases	-	1,186	2,756	-	-	3,942
Total current liabilities	-	(113,018)	187,343	44,288	-	118,613

Edgar Filing: RadNet, Inc. - Form 10-Q

LONG-TERM LIABILITIES

Deferred rent, net of current portion	–	9,579	6,271	–	–	15,850
Line of Credit	–	33,000	–	–	–	33,000
Notes payable, net of current portion	–	536,248	761	–	–	537,009
Obligations under capital leases, net of current portion	–	666	3,087	–	–	3,753
Other non-current liabilities	–	–	8,895	–	–	8,895
Total liabilities	–	466,475	206,357	44,288	–	717,120

EQUITY (DEFICIT)

Total Radnet, Inc.'s equity (deficit)	(2,635)	(2,635)	342,796	9,217	(349,378)	(2,635)
Noncontrolling interests	–	–	–	634	–	634
Total equity (deficit)	(2,635)	(2,635)	342,796	9,851	(349,378)	(2,001)
Total liabilities and equity (deficit)	\$(2,635)	\$463,840	\$549,153	\$54,139	\$(349,378)	\$715,119

RADNET, INC. AND SUBSIDIARIES**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS****For The Three Months Ended March 31, 2013****(in thousands)****(unaudited)**

	Parent	Subsidiary Issuer	Guarantor Subsidiaries	Non-Guarantor Subsidiaries	Eliminations	Consolidated
NET SERVICE FEE REVENUE						
Service fee revenue, net of contractual allowances and discounts	\$–	\$ 37,508	\$ 119,350	\$ 22,904	\$ –	\$ 179,762
Provision for bad debts	–	(1,385)	(4,217)	(1,220)	–	(6,822)
Net service fee revenue	–	36,123	115,133	21,684	–	172,940
OPERATING EXPENSES						
Cost of operations	–	33,236	95,518	20,808	–	149,562
Depreciation and amortization	–	3,128	11,323	309	–	14,760
Loss on sale and disposal of equipment	–	85	85	–	–	170
Severance costs	–	11	110	2	–	123
Total operating expenses	–	36,460	107,036	21,119	–	164,615
(LOSS) INCOME FROM OPERATIONS	–	(337)	8,097	565	–	8,325
OTHER EXPENSES						
Interest expense	–	6,673	5,391	83	–	12,147
Other income	–	–	(2)	–	–	(2)
Total other expenses	–	6,673	5,389	83	–	12,145
(LOSS) INCOME BEFORE INCOME TAXES AND EQUITY IN EARNINGS OF JOINT VENTURES	–	(7,010)	2,708	482	–	(3,820)
Benefit from (provision for) income taxes	–	–	1,254	(6)	–	1,248
Equity in (losses) earnings of consolidated subsidiaries	(1,342)	5,668	500	–	(4,826)	–
Equity in earnings of joint ventures	–	–	1,206	–	–	1,206
NET (LOSS) INCOME	(1,342)	(1,342)	5,668	476	(4,826)	(1,366)
Net loss attributable to noncontrolling interests	–	–	–	(24)	–	(24)
NET (LOSS) INCOME ATTRIBUTABLE TO						

RADNET, INC. COMMON
STOCKHOLDERS

\$(1,342) \$(1,342) \$ 5,668 \$ 500 \$ (4,826) \$(1,342)

RADNET, INC. AND SUBSIDIARIES**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS****For The Three Months Ended March 31, 2012****(in thousands)****(unaudited)**

	Parent	Subsidiary Issuer	Guarantor Subsidiaries	Non-Guarantor Subsidiaries	Eliminations	Consolidated
NET SERVICE FEE REVENUE						
Service fee revenue, net of contractual allowances and discounts	\$–	\$ 34,544	\$ 119,581	\$ 14,375	\$ –	\$ 168,500
Provision for bad debts	–	(1,267)	(4,598)	(619)	–	(6,484)
Net service fee revenue	–	33,277	114,983	13,756	–	162,016
OPERATING EXPENSES						
Cost of operations	–	30,386	91,505	13,509	–	135,400
Depreciation and amortization	–	3,147	11,683	62	–	14,892
Loss (gain) on sale of equipment	–	137	(113)	–	–	24
Severance costs	–	33	390	26	–	449
Total operating expenses	–	33,703	103,465	13,597	–	150,765
(LOSS) INCOME FROM OPERATIONS	–	(426)	11,518	159	–	11,251
OTHER EXPENSES						
Interest expense	–	7,978	5,589	–	–	13,567
Other (income) expenses	–	(1,213)	66	–	–	(1,147)
Total other expenses	–	6,765	5,655	–	–	12,420
(LOSS) INCOME BEFORE INCOME TAXES AND EQUITY IN EARNINGS OF JOINT VENTURES	–	(7,191)	5,863	159	–	(1,169)
Provision for income taxes	–	(2)	(243)	–	–	(245)
Equity in (losses) earnings of consolidated subsidiaries	(111)	7,082	200	–	(7,171)	–
Equity in earnings of joint ventures	–	–	1,262	–	–	1,262
NET (LOSS) INCOME	(111)	(111)	7,082	159	(7,171)	(152)
Net loss attributable to noncontrolling interests	–	–	–	(41)	–	(41)
NET (LOSS) INCOME ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS	\$(111)	\$(111)	\$ 7,082	\$ 200	\$ (7,171)	\$(111)

RADNET, INC. AND SUBSIDIARIES**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS****For The Three Months Ended March 31, 2013****(unaudited)**

	Parent	Subsidiary Issuer	Guarantor Subsidiaries	Non-Guarantor Subsidiaries	Eliminations	Consolidated
CASH FLOWS FROM OPERATING ACTIVITIES						
Net (loss) income	\$(1,342)	\$(1,342)	\$ 5,668	\$ 476	\$ (4,826)	\$(1,366)
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:						
Depreciation and amortization	–	3,128	11,323	309	–	14,760
Provision for bad debt	–	1,385	4,217	1,220	–	6,822
Equity in earnings of consolidated subsidiaries	1,342	(5,668)	(500)	–	4,826	–
Equity in earnings of joint ventures	–	–	(1,206)	–	–	(1,206)
Distributions from joint ventures	–	–	1,921	–	–	1,921
Deferred rent amortization	–	156	254	23	–	433
Amortization of deferred financing cost	–	457	–	–	–	457
Amortization of term loan and bond discount	–	400	–	–	–	400
Loss on sale and disposal of equipment	–	85	85	–	–	170
Stock-based compensation	–	238	714	–	–	952
Changes in operating assets and liabilities, net of assets acquired and liabilities assumed in purchase transactions:						
Accounts receivable	–	–	1,214	(12,996)	–	(11,782)
Other current assets	–	(3,611)	(1,606)	118	–	(5,099)
Other assets	–	225	(330)	–	–	(105)
Deferred revenue	–	–	3	–	–	3
Accounts payable, accrued expenses and other	–	7,957	(10,285)	11,189	–	8,861
Net cash provided by operating activities	–	3,410	11,472	339	–	15,221
CASH FLOWS FROM INVESTING ACTIVITIES						
Purchase of imaging facilities	–	(350)	(3,275)	–	–	(3,625)
Purchase of property and equipment	–	(4,053)	(8,847)	(26)	–	(12,926)
Proceeds from sale of equipment	–	145	125	–	–	270
Proceeds from sale of joint venture interests	–	–	2,640	–	–	2,640

Edgar Filing: RadNet, Inc. - Form 10-Q

Purchase of equity interest in joint ventures	-	-	(724)	-	-	(724)
Net cash used in investing activities	-	(4,258)	(10,081)	(26)	-	(14,365)
CASH FLOWS FROM FINANCING ACTIVITIES						
Principal payments on notes and leases payable	-	(1,424)	(960)	(313)	-	(2,697)
Proceeds from, net of payments, on line of credit	-	1,500	-	-	-	1,500
Proceeds from issuance of common stock	-	469	-	-	-	469
Net provided by (cash used) in financing activities	-	545	(960)	(313)	-	(728)
EFFECT OF EXCHANGE RATE CHANGES ON CASH		(59)	-	-	-	(59)
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	-	(362)	431	-	-	69
CASH AND CASH EQUIVALENTS, beginning of period	-	362	-	-	-	362
CASH AND CASH EQUIVALENTS, end of period	\$-	\$-	\$ 431	\$ -	\$ -	\$ 431

RADNET, INC. AND SUBSIDIARIES**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS****For The Three Months Ended March 31, 2012****(in thousands)****(unaudited)**

	Parent	Subsidiary Issuer	Guarantor Subsidiaries	Non-Guarantor Subsidiaries	Eliminations	Consolidated
CASH FLOWS FROM OPERATING ACTIVITIES						
Net (loss) income	\$(111)	\$(111)	\$ 7,082	\$ 159	\$ (7,171)	\$(152)
Adjustments to reconcile net (loss) income to net cash provided by (used in) operating activities:						
Depreciation and amortization	–	3,147	11,683	62	–	14,892
Provision for bad debt	–	1,267	4,598	619	–	6,484
Equity in (earnings) loss of consolidated subsidiaries	111	(7,082)	(200)	–	7,171	–
Distributions from consolidated subsidiaries	–	–	276	–	(276)	–
Equity in earnings of joint ventures	–	–	(1,262)	–	–	(1,262)
Distributions from joint ventures	–	–	1,575	–	–	1,575
Deferred rent amortization	–	36	252	–	–	288
Amortization of deferred financing cost	–	602	–	–	–	602
Amortization of term loan and bond discount	–	234	–	–	–	234
Loss (gain) on sale of equipment	–	137	(113)	–	–	24
Amortization of cash flow hedge	–	276	–	–	–	276
Stock-based compensation	–	294	881	–	–	1,175
Changes in operating assets and liabilities, net of assets acquired and liabilities assumed in purchase transactions:						
Accounts receivable	–	–	(3,014)	(9,009)	–	(12,023)
Other current assets	–	1,286	(1,472)	(497)	–	(683)
Other assets	–	(19)	(45)	–	–	(64)
Deferred revenue	–	–	86	–	–	86
Accounts payable, accrued expenses and other	–	3,175	(8,028)	8,832	–	3,979
Net cash provided by (used in) operating activities	–	3,242	12,299	166	(276)	15,431
CASH FLOWS FROM INVESTING ACTIVITIES						

Edgar Filing: RadNet, Inc. - Form 10-Q

Purchase of imaging facilities	–	–	(580)	–	–	(580)
Purchase of property and equipment	–	(4,445)	(9,517)	–	–	(13,962)
Proceeds from sale of equipment	–	43	367	–	–	410
Proceeds from sale of imaging facilities	–	–	2,300	–	–	2,300
Purchase of equity interest in joint ventures	–	–	(920)	–	–	(920)
Net cash used in investing activities	–	(4,402)	(8,350)	–	–	(12,752)
CASH FLOWS FROM FINANCING ACTIVITIES						
Principal payments on notes and leases payable	–	(1,406)	(3,073)	–	–	(4,479)
Deferred financing costs	–	–	–	–	–	–
Proceeds from, net of payments on, line of credit	–	2,700	–	–	–	2,700
Payments to counterparties of interest rate swaps, net of amounts received	–	(1,500)	–	–	–	(1,500)
Distributions paid to noncontrolling interests	–	–	–	(302)	276	(26)
Proceeds from issuance of common stock	–	–	–	–	–	–
Net cash used in financing activities	–	(206)	(3,073)	(302)	276	(3,305)
EFFECT OF EXCHANGE RATE CHANGES ON CASH						
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	–	(1,366)	881	(136)	–	(621)
CASH AND CASH EQUIVALENTS, beginning of period	–	1,366	–	1,089	–	2,455
CASH AND CASH EQUIVALENTS, end of period	\$–	\$–	\$ 881	\$ 953	\$–	\$ 1,834

NOTE 9 – SUBSEQUENT EVENTS

On April 3, 2013, we entered into an amendment to the Refinance Agreement. Pursuant to this amendment, we re-priced our current senior secured term loan and borrowed an additional \$40.0 million. More information regarding this amendment is provided under the heading “2013 Amendment to the Refinance Agreement” in Note 1 above.

ITEM 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

Forward-Looking Statements

This quarterly report on Form 10-Q contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements reflect current views about future events and are based on our currently available financial, economic and competitive data and on current business plans. Actual events or results may differ materially depending on risks and uncertainties that may affect our operations, markets, services, prices and other factors.

Statements in this quarterly report concerning our ability to successfully acquire and integrate new operations, to grow our contract management business, our financial guidance, our future cost saving efforts, our increased business from new equipment or operations and our ability to finance our operations are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue," "assumption" or the negative of these terms or other comparable terminology.

Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements.

The factors included in "Risk Factors," in our annual report on Form 10-K for the fiscal year ended December 31, 2012, as amended or supplemented by the information, if any, in Part II – Item 1A below, among others, could cause our actual results to differ materially from those expressed in, or implied by, the forward-looking statements. You should consider the inherent limitations on, and risks associated with, forward-looking statements and not unduly rely on the accuracy of predictions contained in such forward-looking statements. These forward-looking statements speak only as of the date when they are made. Except as required under the federal securities laws or by the rules and regulations of the Securities and Exchange Commission ("SEC"), we do not undertake any obligation to update forward-looking statements to reflect events, circumstances, changes in expectations, or the occurrence of unanticipated events after the date of those statements. Moreover, in the future, the Company, through senior management, may make forward-looking statements that involve the risk factors and other matters described in this Form 10-Q as well as other risk factors subsequently identified, including, among others, those identified in the Company's filings with the SEC on Form 10-K, Form 10-Q and Form 8-K.

We do not undertake any responsibility to release publicly any revisions to these forward-looking statements to take into account events or circumstances that occur after the date of this quarterly report. Additionally, we do not

undertake any responsibility to update you on the occurrence of any unanticipated events which may cause actual results to differ from those expressed or implied by the forward-looking statements contained in this quarterly report.

Overview

We are the leading national provider of freestanding, fixed-site outpatient diagnostic imaging services in the United States based on number of locations and annual imaging revenue. At March 31, 2013, we operated directly or indirectly through joint ventures, 248 centers located in California, Maryland, Florida, Delaware, New Jersey, Rhode Island and New York. Our centers provide physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders and may reduce unnecessary invasive procedures, often reducing the cost and amount of care for patients. Our services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures.

We seek to develop leading positions in regional markets in order to leverage operational efficiencies. Our scale and density within selected geographies provides close, long-term relationships with key payors, radiology groups and referring physicians. Each of our facility managers is responsible for managing relationships with local physicians and payors, meeting our standards of patient service and maintaining profitability. We provide corporate training programs, standardized policies and procedures and sharing of best practices among the physicians in our regional networks.

We derive substantially all of our revenue, directly or indirectly, from fees charged for the diagnostic imaging services performed at our facilities. For the three months ended March 31, 2013, we performed 1,112,967 diagnostic imaging procedures and generated total net service fee revenue of \$172.9 million.

The consolidated financial statements include the accounts of Radnet Management, Inc. (or “Radnet Management”) and Beverly Radiology Medical Group III, a professional partnership (“BRMG”). The consolidated financial statements also include Radnet Management I, Inc., Radnet Management II, Inc., Radiologix, Inc., Radnet Managed Imaging Services, Inc., Delaware Imaging Partners, Inc., New Jersey Imaging Partners, Inc. and Diagnostic Imaging Services, Inc. (“DIS”), all wholly owned subsidiaries of Radnet Management. All of these affiliated entities are referred to collectively as “RadNet”, “we”, “us”, “our” or the “Company” in this report.

Accounting Standards Codification (“ASC”) Section 810-10-15-14 stipulates that generally any entity with a) insufficient equity to finance its activities without additional subordinated financial support provided by any parties, or b) equity holders that, as a group, lack the characteristics specified in the ASC which evidence a controlling financial interest, is considered a Variable Interest Entity (“VIE”). We consolidate all VIEs in which we own a majority voting interest and all VIEs for which we are the primary beneficiary. We determine whether we are the primary beneficiary of a VIE through a qualitative analysis that identifies which variable interest holder has the controlling financial interest in the VIE. The variable interest holder who has both of the following has the controlling financial interest and is the primary beneficiary: (1) the power to direct the activities of the VIE that most significantly impact the VIE’s economic performance and (2) the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE. In performing our analysis, we consider all relevant facts and circumstances, including: the design and activities of the VIE, the terms of the contracts the VIE has entered into, the nature of the VIE’s variable interests issued and how they were negotiated with or marketed to potential investors, and which parties participated significantly in the design or redesign of the entity.

Howard G. Berger, M.D. is our President and Chief Executive Officer, a member of our Board of Directors and is deemed to be the beneficial owner, directly and indirectly, of approximately 13.5% of our outstanding common stock. Dr. Berger also owns, indirectly, 99% of the equity interests in BRMG. BRMG provides all of the professional medical services at the majority of our facilities located in California under a management agreement with us, and employs physicians or contracts with various other independent physicians and physician groups to provide the professional medical services at most of our other California facilities. We generally obtain professional medical services from BRMG in California, rather than provide such services directly or through subsidiaries, in order to comply with California’s prohibition against the corporate practice of medicine. However, as a result of our close relationship with Dr. Berger and BRMG, we believe that we are able to better ensure that medical service is provided at our California facilities in a manner consistent with our needs and expectations and those of our referring physicians, patients and payors than if we obtained these services from unaffiliated physician groups. BRMG is a partnership of ProNet Imaging Medical Group, Inc., Breastlink Medical Group, Inc. and Beverly Radiology Medical Group, Inc., each of which are 99% or 100% owned by Dr. Berger.

John V. Crues III, M.D. is our Medical Director, a member of our Board of Directors and a 1% owner of BRMG. Dr. Crues also owns a controlling interest in three medical groups (“Crues Entities”) which provide professional medical services at our imaging facilities located in Manhattan, New York, which we acquired through our December 31, 2012 acquisition of Lenox Hill.

RadNet provides non-medical, technical and administrative services to BRMG and the Crues Entities for which it receives a management fee, per the related management agreements. Through these management agreements and our

relationship with both Dr. Berger and Dr. Crues, we have exclusive authority over all non-medical decision making related to the ongoing business operations of BRMG and the Crues Entities. Through our management agreements with BRMG and the Crues Entities, we determine the annual budget of BRMG and the Crues Entities and make all physician employment decisions. BRMG and the Crues Entities both have insignificant operating assets and liabilities, and de minimis equity. Through the management agreements with us, all cash flows of both BRMG and the Crues Entities are transferred to us.

We have determined that BRMG and the Crues Entities are variable interest entities, and that we are the primary beneficiary, and consequently, we consolidate the revenue and expenses of each. BRMG and the Crues Entities combined recognized \$17.4 million and \$12.7 million of revenue, net of management service fees to RadNet, Inc., for the three months ended March 31, 2013 and 2012, respectively, and \$17.4 million and \$12.7 million of operating expenses for the three months ended March 31, 2013 and 2012, respectively. RadNet, Inc. recognized in its condensed consolidated statement of operations \$80.6 million and \$63.1 million of total billed net service fee revenue relating to these entities for the three months ended March 31, 2013 and 2012, respectively, of which \$63.2 million and \$50.4 million was for management services provided to BRMG and the Crues Entities relating primarily to the technical portion of total billed revenue for the three months ended March 31, 2013 and 2012, respectively. The cash flows of BRMG and the Crues Entities are included in the accompanying consolidated statements of cash flows. All intercompany balances and transactions have been eliminated in consolidation. In our consolidated balance sheets at March 31, 2013 and December 31, 2012, we have included approximately \$60.5 million and \$51.8 million, respectively, of accounts receivable and approximately \$8.8 million and \$6.3 million, respectively, of accounts payable and accrued liabilities, related to BRMG and the Crues Entities combined.

The creditors of both BRMG and the Crues Entities do not have recourse to our general credit and there are no other arrangements that could expose us to losses. However, both BRMG and the Crues Entities are managed to recognize no net income or net loss and, therefore, RadNet may be required to provide financial support to cover any operating expenses in excess of operating revenues.

Aside from centers in California and Manhattan, New York where we contract with BRMG and the Crues Entities for the provision of professional medical services, at the remaining centers in California and at all of the centers which are located outside of California except for Manhattan, New York, we have entered into long-term contracts with independent radiology groups in the area to provide physician services at those facilities. These third party radiology practices provide professional services, including supervision and interpretation of diagnostic imaging procedures, in our diagnostic imaging centers. The radiology practices maintain full control over the provision of professional services. The contracted radiology practices generally have outstanding physician and practice credentials and reputations; strong competitive market positions; a broad sub-specialty mix of physicians; a history of growth and potential for continued growth. In these facilities we enter into long-term agreements with radiology practice groups (typically 40 years). Under these arrangements, in addition to obtaining technical fees for the use of our diagnostic imaging equipment and the provision of technical services, we provide management services and receive a fee based on the practice group's professional revenue, including revenue derived outside of our diagnostic imaging centers. We own the diagnostic imaging equipment and, therefore, receive 100% of the technical reimbursements associated with imaging procedures. The radiology practice groups retain the professional reimbursements associated with imaging procedures after deducting management service fees paid to us. We have no financial controlling interest in the independent (non-BRMG) radiology practices; accordingly, we do not consolidate the financial statements of those practices in our consolidated financial statements.

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X and, therefore, do not include all information and footnotes necessary for a fair presentation of financial position, results of operations and cash flows in conformity with U.S. generally accepted accounting principles complete financial statements; however, in the opinion of our management, all adjustments consisting of normal recurring adjustments necessary for a fair presentation of the financial position, results of operations and cash flows for the interim periods ended March 31, 2013 and 2012 have been made. The results of operations for any interim period are not necessarily indicative of the results for a full year. These interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes thereto contained in our annual report on Form 10-K for the year ended December 31, 2012 as amended.

Critical Accounting Policies

Use of Estimates

Our discussion and analysis of financial condition and results of operations are based on our consolidated financial statements that were prepared in accordance with U.S. generally accepted accounting principles, or

GAAP. Management makes estimates and assumptions when preparing financial statements. These estimates and assumptions affect various matters, including:

- our reported amounts of assets and liabilities in our consolidated balance sheets at the dates of the financial statements;
- our disclosure of contingent assets and liabilities at the dates of the financial statements; and
- our reported amounts of net revenue and expenses in our consolidated statements of operations during the reporting periods.

These estimates involve judgments with respect to numerous factors that are difficult to predict and are beyond management's control. As a result, actual amounts could differ materially from these estimates.

The Securities and Exchange Commission, or SEC, defines critical accounting estimates as those that are both most important to the portrayal of a company's financial condition and results of operations and require management's most difficult, subjective or complex judgment, often as a result of the need to make estimates about the effect of matters that are inherently uncertain and may change in subsequent periods. In Note 2 to our consolidated financial statements in our annual report on Form 10-K for the year ended December 31, 2012 as amended, we discuss our significant accounting policies, including those that do not require management to make difficult, subjective or complex judgments or estimates. The most significant areas involving management's judgments and estimates are described below.

During the period covered in this report, there were no material changes to the critical accounting estimates we use, and have described in our annual report on Form 10-K for the fiscal year ended December 31, 2012 as amended.

Revenues

Service fee revenue, net of contractual allowances and discounts, consists of net patient fees received from various payers and patients themselves based mainly upon established contractual billing rates, less allowances for contractual adjustments. As it relates to BRMG centers, this service fee revenue includes payments for both the professional medical interpretation revenue recognized by BRMG as well as the payment for all other aspects related to our providing the imaging services, for which we earn management fees from BRMG. As it relates to non-BRMG centers, this service fee revenue is earned through providing the administration of the non-medical functions relating to the professional medical practice at our non-BRMG centers, including among other functions, provision of clerical and administrative personnel, bookkeeping and accounting services, billing and collection, provision of medical and office supplies, secretarial, reception and transcription services, maintenance of medical records, and advertising, marketing and promotional activities.

Service fee revenues are recorded during the period the patient services are provided based upon the estimated amounts due from the patients and third-party payers. Third-party payers include federal and state agencies (under the Medicare and Medicaid programs), managed care health plans, commercial insurance companies and employers. Estimates of contractual allowances under managed care health plans are based upon the payment terms specified in the related contractual agreements. Contractual payment terms in managed care agreements are generally based upon predetermined rates per discounted fee-for-service rates. We also record a provision for doubtful accounts (based primarily on historical collection experience) related to patients and copayment and deductible amounts for patients who have health care coverage under one of our third-party payers.

Our service fee revenue, net of contractual allowances and discounts less the provision for bad debts for the three months ended March 31, are summarized in the following table (in thousands):

	2013	2012
Commercial Insurance	\$97,685	\$91,745
Managed Care Capitated Payors	22,583	21,626
Medicare	35,713	34,077
Medicaid	5,777	5,570
Other	18,004	15,483
Service fee revenue, net of contractual allowances and discounts	179,762	168,500
Provision for bad debts	(6,822)	(6,484)
Net service fee revenue	\$172,940	\$162,016

The break-out of our service fee revenue, net of contractual allowances and discounts, is calculated based upon global payments received from consolidated imaging centers from dates of service during each respective period illustrated.

Accounts Receivable

Substantially all of our accounts receivable are due under fee-for-service contracts from third party payors, such as insurance companies and government-sponsored healthcare programs, or directly from patients. Services are generally provided pursuant to one-year contracts with healthcare providers. Receivables generally are collected within industry norms for third-party payors. We continuously monitor collections from our payors and maintain an allowance for bad debts based upon specific payor collection issues that we have identified and our historical experience.

Provision for Bad Debts

Although outcomes vary, our policy is to attempt to collect amounts due from patients, including co-payments and deductibles due from patients with insurance, at the time of service. We provide for an allowance against accounts receivable that could become uncollectible by establishing an allowance to reduce the carrying value of such receivables to their estimated net realizable value. We estimate this allowance based on the aging of our accounts receivable by each type of payer over an 18-month look-back period, and other relevant factors. A significant portion of our provision for bad debt relates to co-payments and deductibles owed to us by patients with insurance. There are various factors that can impact collection trends, such as changes in the economy, which in turn have an impact on the increased burden of co-payments and deductibles to be made by patients with insurance. These factors continuously change and can have an impact on collection trends and our estimation process.

Depreciation and Amortization of Long-Lived Assets

We depreciate our long-lived assets over their estimated economic useful lives with the exception of leasehold improvements where we use the shorter of the assets useful lives or the lease term of the facility for which these assets are associated.

Deferred Tax Assets

Income tax expense is computed using an asset and liability method and using expected annual effective tax rates. Under this method, deferred income tax assets and liabilities result from temporary differences in the financial reporting bases and the income tax reporting bases of assets and liabilities. The measurement of deferred tax assets is reduced, if necessary, by the amount of any tax benefit that, based on available evidence, is not expected to be realized. When it appears more likely than not that deferred taxes will not be realized, a valuation allowance is recorded to reduce the deferred tax asset to its estimated realizable value. For net deferred tax assets we consider estimates of future taxable income, including tax planning strategies, in determining whether our net deferred tax assets are more likely than not to be realized. At March 31, 2013, we determined that approximately \$61.8 million of our net deferred tax assets are more likely than not to be realized.

Valuation of Goodwill and Long-Lived Assets

Goodwill at March 31, 2013 totaled \$197.1 million. Goodwill is recorded as a result of business combinations. Management evaluates goodwill, at a minimum, on an annual basis and whenever events and changes in circumstances suggest that the carrying amount may not be recoverable in accordance with ASC 350, *Intangibles – Goodwill and Other*. Impairment of goodwill is tested at the reporting unit level by comparing the reporting unit's carrying amount, including goodwill, to the fair value of the reporting unit. The fair value of a reporting unit is estimated using a combination of the income or discounted cash flows approach and the market approach, which uses comparable market data. If the carrying amount of the reporting unit exceeds its fair value, goodwill is considered impaired and a second step is performed to measure the amount of impairment loss, if any. We tested goodwill for impairment on October 1, 2012. Based on our test, we noted no impairment related to goodwill as of October 1, 2012. However, if estimates or the related assumptions change in the future, we may be required to record impairment charges to reduce the carrying amount of goodwill.

We evaluate our long-lived assets (property and equipment) and intangibles, other than goodwill, for impairment whenever indicators of impairment exist. The accounting standards require that if the sum of the undiscounted expected future cash flows from a long-lived asset or definite-lived intangible is less than the carrying value of that asset, an asset impairment charge must be recognized. The amount of the impairment charge is calculated as the excess of the asset's carrying value over its fair value, which generally represents the discounted future cash flows from that asset or in the case of assets we expect to sell, at fair value less costs to sell. No indicators of impairment

were identified with respect to our long-lived assets as of March 31, 2013.

Recent Accounting Standards

Reclassifications Out of Accumulated Other Comprehensive Income. In February 2013, the Financial Accounting Standards Board (FASB) issued guidance for the reporting of amounts reclassified out of accumulated other comprehensive income. The new guidance requires entities to report the effect of significant reclassifications out of accumulated other comprehensive income on the respective line items in net income if the amount being reclassified is required under U.S. generally accepted accounting principles (GAAP) to be reclassified in its entirety to net income. The new guidance does not change the current requirements for reporting net income or other comprehensive income in financial statements and is effective prospectively for reporting periods beginning after December 15, 2012. The adoption of this new guidance in 2013 did not impact our financial position, results of operations or cash flows.

Balance Sheet Offsetting. In December 2012, the FASB issued guidance for new disclosure requirements related to the nature of an entity's rights of set-off and related arrangements associated with its financial instruments and derivative instruments. The new guidance is effective for annual reporting periods, and interim periods within those years, beginning on or after January 1, 2013. The adoption of this new guidance in 2013 did not impact our financial position, results of operations or cash flows.

Recent Developments

On April 3, 2013, we entered into an amendment to the Refinance Agreement. Pursuant to this amendment, we re-priced our current senior secured term loan and borrowed an additional \$40.0 million under the senior secured loan facility. . More information regarding this amendment is provided under the heading “Liquidity and Capital Resources” below and more information regarding the Refinance Agreement is provided in Note 1 to our unaudited condensed consolidated financial statements included in Item 1, Part I of this quarterly report.

On April 1, 2013, the Centers for Medicare and Medicaid Services (“CMS”) published its Contract Year 2014 Final Call Letter. In the Final Call Letter, CMS made the assumption that Congressional action would be taken to prospectively fix the Medicare physician fee schedule’s sustainable growth rate formula and that there would be a 0% change in the Medicare physician fee schedule rates for 2014. Based on these assumptions, CMS estimated a 3.3% increase in the 2014 Medicare Advantage rates.

Facility Acquisitions and Dispositions

On February 28, 2013, we completed our acquisition of a multi-modality imaging center located in Brooklyn, New York by exercising a \$1.00 purchase option to acquire an initial 50% interest (we acquired this option through our December 31, 2012 acquisition of Lenox Hill Radiology which we valued at approximately \$2.5 million) and then by purchasing the remaining 50% interest from the existing partner for approximately \$2.4 million in cash. We have made a fair value determination of the acquired assets and assumed liabilities and approximately \$813,000 of fixed assets, \$4.2 million of goodwill and \$124,000 of notes payable was recorded with respect to this transaction.

On February 8, 2013, we completed the acquisition of a multi modality imaging center located in Manhattan, New York for \$1.0 million. The facility provides MRI, CT, mammography, ultrasound and X-ray services. We have made a fair value determination of the acquired assets and assumed liabilities and approximately \$1.0 million of fixed assets was recorded with respect to this transaction.

On February 5, 2013, we sold a 10% interest in a wholly owned limited liability company consisting of two multi-modality imaging centers located in Bel Air, Maryland for approximately \$2.6 million. On the date of sale, we recorded approximately \$439,000 of non-controlling interests and \$2.2 million of additional paid in capital with respect to this transaction.

On January 30, 2013, we purchased for \$430,000 an additional 20.9% interest in a joint venture multi-modality imaging center located in Manhattan, New York of which we initially held a 31.5% interest from our December 31, 2012 acquisition of Lenox Hill Radiology which we valued at approximately \$648,000. This additional 20.9% interest

gave us a 52.4% controlling interest and so accordingly, we began consolidating this imaging center, recording all of its assets and liabilities at their fair value at January 30, 2013. We have made a fair value determination of the acquired assets and assumed liabilities and approximately \$358,000 of working capital, \$2.1 million of fixed assets, \$2.0 million of goodwill, \$2.4 million of notes payable and \$979,000 of non-controlling interests was recorded with respect to this transaction.

On January 1, 2013, we completed our acquisition of a breast surgery practice located in Mission Viejo, California for \$350,000. We have made a fair value determination of the acquired assets and assumed liabilities and approximately \$135,000 of working capital, \$30,000 of fixed assets and \$185,000 of goodwill was recorded with respect to this transaction.

On December 31, 2012, we completed our acquisition of Lenox Hill Radiology, consisting of three multi-modality imaging centers as well as three additional x-ray facilities all located in Manhattan, New York. We also acquired in this transaction a 31.5% interest in a joint venture multi-modality imaging center in Manhattan, New York and an option to purchase a 50% interest in a multi-modality imaging center located in Brooklyn, New York for \$1.00. The purchase price consisted of approximately \$28.4 million in cash. With the services of an external valuation expert, we have made a final fair value determination of the acquired assets and assumed liabilities and \$4.5 million of working capital, \$8.7 million of fixed assets, which is approximately \$1.5 million higher than our initial estimate, \$648,000 of joint venture interests, \$2.5 million in a \$1.00 joint venture purchase option, \$100,000 of intangible assets, \$14.0 million of goodwill and indefinite life intangibles which is approximately \$1.3 million lower than our initial estimate, the assumption of approximately \$650,000 of other liabilities, which is approximately \$150,000 higher than our initial estimate, and \$1.3 million of capital lease debt was recorded with respect to this transaction.

Results of Operations

The following table sets forth, for the periods indicated, the percentage that certain items in the statements of operations bears to service fee revenue, net of contractual allowances and discounts.

RADNET, INC. AND SUBSIDIARIES**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**

	Three Months Ended March 31,	
	2013	2012
NET SERVICE FEE REVENUE		
Service fee revenue, net of contractual allowances and discounts	100.0%	100.0%
Provision for bad debts	-3.8%	-3.8%
Net service fee revenue	96.2%	96.2%
OPERATING EXPENSES		
Cost of operations	83.2%	80.4%
Depreciation and amortization	8.2%	8.8%
Loss on sale and disposal of equipment	0.1%	0.0%
Severance costs	0.1%	0.3%
Total operating expenses	91.6%	89.5%
INCOME FROM OPERATIONS	4.6%	6.7%
OTHER EXPENSES		
Interest expense	6.8%	8.1%
Other income	0.0%	-0.7%
Total other expenses	6.8%	7.4%
LOSS BEFORE INCOME TAXES AND EQUITY IN EARNINGS OF JOINT VENTURES	-2.1%	-0.7%
Benefit from (provision for) income taxes	0.7%	-0.1%
Equity in earnings of joint ventures	0.7%	0.7%
NET LOSS	-0.8%	-0.1%
Net loss attributable to noncontrolling interests	0.0%	0.0%
NET LOSS ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS	-0.7%	-0.1%

Three Months Ended March 31, 2013 Compared to the Three Months Ended March 31, 2012

Service Fee Revenue

Service fee revenue for the three months ended March 31, 2013 was \$179.8 million compared to \$168.5 million for the three months ended March 31, 2012, an increase of \$11.3 million, or 6.7%.

Service fee revenue, including only those centers which were in operation throughout the first quarters of both 2013 and 2012 decreased \$11.9 million, or 7.1%. The comparison of this year's first quarter to the same quarter last year was greatly affected by certain factors that made last year's first quarter performance comparatively stronger. One of these is the fact that last year's first quarter had one additional workday associated with the leap year. Another is the fact that last year's first quarter was operated during an exceptionally mild winter in the northeast, allowing our centers in the northeast to remain open without incident throughout that period. This comparison excludes revenue contributions from centers that were acquired or divested subsequent to January 1, 2012. For the three months ended March 31, 2013, service fee revenue from centers that were acquired subsequent to January 1, 2012 and excluded from the above comparison was \$24.1 million. For the three months ended March 31, 2012, service fee revenue from centers that were acquired subsequent to January 1, 2012 and excluded from the above comparison was \$921,000.

Provision for Bad Debts

Provision for bad debts increased \$338,000, or 5.2%, to \$6.8 million, or 3.8% of service fee revenue, for the three months ended March 31, 2013 compared to \$6.5 million, or 3.8% of service fee revenue, for the three months ended March 31, 2012. This increase is in line with the increase in service fee revenues.

Operating Expenses

Cost of operations for the three months ended March 31, 2013 increased approximately \$14.2 million, or 10.5%, from \$135.4 million for the three months ended March 31, 2012 to \$149.6 million for the three months ended March 31, 2013. The following table sets forth our cost of operations and total operating expenses for the three months ended March 31, 2013 and 2012 (in thousands):

	Three Months Ended March 31,	
	2013	2012
Salaries and professional reading fees, excluding stock-based compensation	\$81,691	\$74,184
Stock-based compensation	952	1,175
Building and equipment rental	16,303	14,908
Medical supplies	9,178	9,999
Other operating expenses *	41,438	35,134
Cost of operations	149,562	135,400
Depreciation and amortization	14,760	14,892
Loss on sale and disposal of equipment	170	24
Severance costs	123	449
Total operating expenses	\$164,615	\$150,765

*Includes billing fees, office supplies, repairs and maintenance, insurance, business tax and license, outside services, utilities, marketing, travel and other expenses.

Salaries and professional reading fees, excluding stock-based compensation and severance

Salaries and professional reading fees increased \$7.5 million, or 10.2%, to \$81.7 million for the three months ended March 31, 2013 compared to \$74.2 million for the three months ended March 31, 2012.

Salaries and professional reading fees, including only those centers which were in operation throughout the first quarters of both 2013 and 2012, decreased \$1.1 million, or 1.4%. This 1.4% decrease is in line with our decrease in procedure volumes at these centers. This comparison excludes expenses from centers that were acquired or divested subsequent to January 1, 2012. For the three months ended March 31, 2013, salaries and professional reading fees from centers that were acquired subsequent to January 1, 2012 and excluded from the above comparison was approximately \$8.6 million. For the three months ended March 31, 2012, salaries and professional reading fees from centers that were acquired subsequent to January 1, 2012 and excluded from the above comparison was approximately \$65,000.

Stock-based compensation

Stock-based compensation decreased \$223,000, or 19.0%, to approximately \$952,000 for the three months ended March 31, 2013 compared to \$1.2 million for the three months ended March 31, 2012. The decrease is due to fewer equity compensation instruments being issued during the three months ended March 31, 2013 compared to the same period last year.

Building and equipment rental

Building and equipment rental expenses increased \$1.4 million, or 9.4%, to \$16.3 million for the three months ended March 31, 2013 compared to \$14.9 million for the three months ended March 31, 2012.

Building and equipment rental expenses, including only those centers which were in operation throughout the first quarters of both 2013 and 2012, decreased \$180,000, or 1.2%. This 1.2% decrease is primarily due to equipment lease buy-outs occurring subsequent to March 31, 2012. This comparison excludes expenses from centers that were acquired or divested subsequent to January 1, 2012. For the three months ended March 31, 2013, building and equipment rental expenses from centers that were acquired subsequent to January 1, 2012 and excluded from the above comparison was approximately \$1.6 million. For the three months ended March 31, 2012, building and equipment rental expenses from centers that were acquired subsequent to January 1, 2012 and excluded from the above comparison was \$44,000.

Medical supplies

Medical supplies expense decreased \$821,000, or 8.2%, to \$9.2 million for the three months ended March 31, 2013 compared to \$10.0 million for the three months ended March 31, 2012.

Medical supplies expenses, including only those centers which were in operation throughout the first quarters of both 2013 and 2012, decreased \$1.7 million, or 17.5%. This 17.5% decrease is due to the reduction in our procedure volumes as well as an increase in rebates we receive from certain vendors. This comparison excludes expenses from centers that were acquired or divested subsequent to January 1, 2012. For the three months ended March 31, 2013, medical supplies expense from centers that were acquired subsequent to January 1, 2012 and excluded from the above comparison was \$931,000.

Depreciation and amortization

Depreciation and amortization decreased \$132,000, or 0.9%, to \$14.8 million for the three months ended March 31, 2013 compared to the same period last year. The decrease is primarily due to several of our assets completing their depreciation schedules subsequent to the end of our first quarter of 2012.

Interest expense

Interest expense for the three months ended March 31, 2013 decreased approximately \$1.4 million, or 10.5%, to \$12.1 million for the three months ended March 31, 2013 compared to \$13.6 million for the three months ended March 31, 2012. Interest expense for the three months ended March 31, 2013 included \$857,000 of amortization of deferred loan costs and discount on issuance of debt. Interest expense for the three months ended March 31, 2012 included \$836,000 of amortization of deferred loan costs and discount on issuance of debt as well as \$276,000 of amortization of Accumulated Other Comprehensive Loss associated with fair value adjustments to our interest rate swaps accumulated prior to April 6, 2010, the date of our debt refinancing. See "Liquidity and Capital Resources" below for more details on our debt refinancing. Excluding these adjustments to interest expense for each period, interest expense decreased approximately \$1.3 million for the three months ended March 31, 2013 compared to the three months ended March 31, 2012. This decrease was primarily due to a reduction in interest relating to our interest rate swaps, which contractually ended in November 2012.

Other income

For the three months ended March 31, 2012, we recorded approximately \$1.2 million of other income primarily related to fair value adjustments on our interest rate swaps.

Equity in earnings from unconsolidated joint ventures

For the three months ended March 31, 2013, we recognized equity in earnings from unconsolidated joint ventures of \$1.2 million compared to \$1.3 million for the three months ended March 31, 2012. This decrease is primarily due to a change in estimated collection rates applied to revenue recognized subsequent to March 31, 2012.

Adjusted EBITDA

We use both GAAP and non-GAAP metrics to measure our financial results. We believe that, in addition to GAAP metrics, these non-GAAP metrics assist us in measuring our cash generated from operations and ability to service our debt obligations. We believe this information is useful to investors and other interested parties because we are highly leveraged and our non-GAAP metrics removes non-cash and certain other charges that occur in the affected period and provides a basis for measuring the Company's financial condition against other quarters.

One non-GAAP measure we believe assists us is Adjusted EBITDA. We define Adjusted EBITDA as earnings before interest, taxes, depreciation and amortization, each from continuing operations and exclude losses or gains on the disposal of equipment, other income or loss, loss on debt extinguishments, bargain purchase gains and non-cash equity compensation. Adjusted EBITDA includes equity earnings in unconsolidated operations and subtracts allocations of earnings to non-controlling interests in subsidiaries, and is adjusted for non-cash or extraordinary and one-time events taking place during the period.

Adjusted EBITDA is reconciled to its nearest comparable GAAP financial measure, net income (loss) attributable to RadNet, Inc. common stockholders. Adjusted EBITDA is a non-GAAP financial measure used as an analytical indicator by us and the healthcare industry to assess business performance, and is a measure of leverage capacity and ability to service debt. Adjusted EBITDA should not be considered a measure of financial performance under GAAP, and the items excluded from Adjusted EBITDA should not be considered in isolation or as alternatives to net income, cash flows generated by operating, investing or financing activities or other financial statement data presented in the consolidated financial statements as an indicator of financial performance or liquidity. As Adjusted EBITDA is not a measurement determined in accordance with GAAP and is therefore susceptible to varying methods of calculation, this metric, as presented, may not be comparable to other similarly titled measures of other companies.

The following is a reconciliation of GAAP net loss to Adjusted EBITDA for the three months ended March 31, 2013 and 2012, respectively:

	Three Months Ended March 31, 2013 2012	
Net Loss Attributable to RadNet, Inc. Common Stockholders	\$(1,342)	\$(111)
Plus (Benefit from) provision for Income Taxes	(1,248)	245
Minus Other Income	(2)	(1,147)
Plus Interest Expense	12,147	13,567
Plus Severance Costs	123	449
Plus Loss on Sale and Disposal of Equipment	170	24
Plus Depreciation and Amortization	14,760	14,892
Plus Non Cash Employee Stock-Based Compensation	952	1,175
Adjusted EBITDA	\$25,560	\$29,094

Liquidity and Capital Resources

We had cash and cash equivalents of \$431,000 and accounts receivable of \$134.9 million at March 31, 2013, compared to cash and cash equivalents of \$362,000 and accounts receivable of \$129.2 million at December 31, 2012. We had a working capital balance of \$37.8 million and \$37.3 million at March 31, 2013 and December 31, 2012, respectively. We had a net loss attributable to RadNet, Inc. common stockholders for the three months ended March 31, 2013 and 2012 of \$3.0 million and 111,000, respectively. We also had a stockholders' equity deficit of \$19,000 and \$2.0 million at March 31, 2013 and December 31, 2012, respectively.

We operate in a capital intensive, high fixed-cost industry that requires significant amounts of capital to fund operations. In addition to operations, we require a significant amount of capital for the initial start-up and development of new diagnostic imaging facilities, the acquisition of additional facilities and new diagnostic imaging equipment. Because our cash flows from operations have been insufficient to fund all of these capital requirements,

we have depended on the availability of financing under credit arrangements with third parties.

Based on our current level of operations, we believe that cash flow from operations and available cash, together with available borrowings from our senior secured credit facilities, will be adequate to meet our short-term and long-term liquidity needs. Our future liquidity requirements will be for working capital, capital expenditures, debt service and general corporate purposes. Our ability to meet our working capital and debt service requirements, however, is subject to future economic conditions and to financial, business and other factors, many of which are beyond our control. If we are not able to meet such requirements, we may be required to seek additional financing. There can be no assurance that we will be able to obtain financing from other sources on terms acceptable to us, if at all.

On a continuing basis, we also consider various transactions to increase shareholder value and enhance our business results, including acquisitions, divestitures and joint ventures. These types of transactions may result in future cash proceeds or payments but the general timing, size or success of any acquisition, divestiture or joint venture effort and the related potential capital commitments cannot be predicted. We expect to fund any future acquisitions primarily with cash flow from operations and borrowings, including borrowing from amounts available under our senior secured credit facilities or through new equity or debt issuances.

We and our subsidiaries or affiliates may from time to time, in our or their sole discretion, purchase, repay, redeem or retire any of our outstanding debt or equity securities in privately negotiated or open market transactions, by tender offer or otherwise. However, we have no formal plan of doing so at this time.

Included in our condensed consolidated balance sheet at March 31, 2013 are \$198.1 million of senior notes (net of unamortized discounts of \$1.9 million), \$341.1 million of senior secured term loan debt (net of unamortized discounts of \$7.2 million) and \$34.5 million aggregate principal amount outstanding under the revolving credit facility.

Accordingly, the par values outstanding of our senior notes and senior secured term loan are \$200 million and \$348.25 million, respectively.

Sources and Uses of Cash

Cash provided by operating activities was \$15.2 million and \$15.4 million for the three months ended March 31, 2013 and 2012, respectively.

Cash used in investing activities was \$14.4 million and \$12.8 million for the three months ended March 31, 2013 and 2012, respectively. For the three months ended March 31, 2013, we purchased property and equipment for approximately \$12.9 million, acquired the assets and businesses of additional imaging facilities for approximately \$3.6 million (see Note 2 to the condensed consolidated financial statements of this quarterly report), and purchased additional equity interests in non-consolidated joint ventures for \$724,000. Offsetting our cash used in investing activities was \$2.6 million in proceeds from the sale of a non-controlling interest in one of our consolidated joint ventures, and \$270,000 of proceeds from the sale of imaging equipment.

Cash used in financing activities was \$728,000 and \$3.3 million for the three months ended March 31, 2013 and 2012, respectively. The cash used in financing activities for the three months ended March 31, 2013, was primarily due to principal payments on our notes offset in part by net proceeds from borrowings under our line of credit.

Financing Activities

In April 2010, we completed a series of transactions for an aggregate of \$585 million. As part of the transactions that were completed, our wholly owned subsidiary, Radnet Management, Inc., issued and sold \$200.0 million in 10 3/8% senior unsecured notes due 2018 (the "senior notes"). The senior notes initially issued on April 6, 2010 in a private placement were subsequently publicly offered for exchange enabling holders of the outstanding senior notes to

exchange the outstanding notes for publicly registered exchange notes with nearly identical terms. The exchange offer was completed on February 14, 2011. Additional information regarding the senior notes is provided in Note 1 to our unaudited condensed consolidated financial statements included in Item 1, Part 1 of this quarterly report.

In addition to the issuance of senior notes, Radnet Management entered into a Credit and Guaranty Agreement with a syndicate of lenders (the "Credit Agreement"), whereby Radnet Management obtained \$385.0 million in senior secured first-lien bank financing, consisting of (i) a \$285.0 million, six-year term loan facility and (ii) a \$100.0 million, five-year revolving credit facility, including a swing line subfacility and a letter of credit subfacility (collectively, the "Credit Facilities").

In October 2012, we completed a refinancing of the Credit Facility by entering into a new Credit and Guaranty Agreement with a syndicate of banks and other financial institutions (the "Refinance Agreement"). The total amount of refinancing was \$451.25 million, consisting of (i) a \$350 million senior secured term loan and (ii) a \$101.25 million senior secured revolving credit facility. The obligations of Radnet Management, Inc. under the Refinance Agreement are guaranteed by RadNet, Inc. and all of Radnet Management's current and future domestic subsidiaries and certain of our affiliates. The obligations under the Refinance Agreement, including the guarantees, are secured by a perfected first-priority security interest in all of Radnet Management's and the guarantors' tangible and intangible assets, including, but not limited to, pledges of equity interests of Radnet Management and all of our current and future domestic subsidiaries.

The termination date for the \$350 million term loan is the earliest to occur of (i) the sixth anniversary of the closing date (October 10, 2012), (ii) the date on which all of the term loans shall become due and payable in full under the Refinance Agreement whether by acceleration or otherwise and (iii) October 1, 2017 if our senior notes due 2018 have not been refinanced by such date. The termination date for the \$101.25 million revolving credit facility is the earliest to occur of (i) the fifth anniversary of the closing date, (ii) the date the revolving credit facility is permanently reduced to zero pursuant to section 2.13(b) of the Refinance Agreement, (iii) the date of the termination of the revolving credit facility pursuant to section 8.01 of the Refinance Agreement and (iv) October 1, 2017 if our senior notes due 2018 have not been refinanced by such date.

In connection with the refinancing of the Credit Facilities, Radnet Management used the net proceeds to repay in full its existing six year term loan facility for \$277.9 million in principal amount outstanding, which would have matured on April 6, 2016, and its revolving credit facility for \$59.8 million in principal amount outstanding, which would have matured on April 6, 2015.

The terms and conditions of the Refinance Agreement are more fully described in Note 1 to our unaudited condensed consolidated financial statements included above in Item 1, Part I of this quarterly report.

On April 3, 2013, we entered into a first amendment to the Refinance Agreement. Pursuant to this amendment, we re-priced our current senior secured term loans and borrowed an additional \$40.0 million under the senior secured loan facility. Pursuant to the amendment to the Refinance Agreement, the interest rate spread over LIBOR for the senior secured term loans has been reduced from 4.25% to 3.25% and the interest rate spread over the alternative base rate for the senior secured term loans has been reduced from 3.25% to 2.25%. The minimum LIBOR rate underlying the senior secured term loans has been reduced from 1.25% to 1.0%. The other material terms of Refinance Agreement remain unchanged and are described in Note 1 to our unaudited condensed consolidated financial statements included above in Item 1, Part I of this quarterly report.

ITEM 3. Quantitative and Qualitative Disclosures about Market Risk

Foreign Currency Exchange Risk. We sell our services exclusively in the United States and receive payment for our services exclusively in United States dollars. As a result, our financial results are unlikely to be affected by factors such as changes in foreign currency, exchange rates or weak economic conditions in foreign markets.

After the completion of the acquisition of Image Medical Corporation, the parent of eRAD, Inc. on October 1, 2010, we maintain research and development facilities in Prince Edward Island, Canada and Budapest, Hungary for which expenses are paid in the local currency. Accordingly, we do have currency risk resulting from fluctuations between such local currency and the United States Dollar. At the present time, we do not have any foreign exchange currency contracts to mitigate this risk. Fluctuations in foreign exchange rates could impact future operating results. A hypothetical 1% increase in the rate of exchange of foreign currencies against the dollar for 2013 would have resulted in an increase of approximately \$10,000 in our operating expenses for the year.

Interest Rate Sensitivity. RadNet Inc. pays interest on various types of debt instruments to its suppliers, investors and lending institutions. The agreements entail either fixed or variable interest rates. Instruments which have fixed rates include leases on equipment and interest due on our \$200 million outstanding senior notes. Variable rate interest obligations relate primarily to amounts borrowed under our outstanding credit facilities, which allows elections of either LIBOR or prime rates of interest. Under the Refinance Agreement's LIBOR election facility, borrowed funds bear a 1.25% floor or 6 month LIBOR plus an applicable margin of 4.25%. At March 31, 2013, we had \$348.3 million outstanding subject to a LIBOR election. As the LIBOR floor exceeds the current spot rate of 6 month LIBOR, the spot rate would have to increase more than 81 basis points before an additional interest expense would be

accrued. An increase of 181 basis points would be necessary to realize a hypothetical 1% increase in the borrowing rate and an annual increase of \$3.5 million of interest expense. At March 31, 2013, an additional \$35.4 million was tied to the prime rate. A hypothetical 1% increase in the prime rate for 2012-2013 would have resulted in an annual increase of approximately \$354,000.

ITEM 4. Controls and Procedures

We maintain disclosure controls and procedures that are designed to provide reasonable assurance that material information is: (1) gathered and communicated to our management, including our principal executive and financial officers, on a timely basis; and (2) recorded, processed, summarized, reported and filed with the SEC as required under the Securities Exchange Act of 1934, as amended.

Our management, with the participation of our chief executive officer and chief financial officer, evaluated the effectiveness of our disclosure controls and procedures as of March 31, 2013. Based on such evaluation, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures were effective for their intended purpose described above.

Changes in Internal Control over Financial Reporting

No changes were made in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) during our most recent fiscal quarter that has materially affected, or is likely to materially affect, our internal control over financial reporting.

Limitations on Disclosure Controls and Procedures.

Our management, including our chief executive officer and chief financial officer, does not expect that our disclosure controls or internal controls over financial reporting will prevent all errors or all instances of fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system's objectives will be met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and any design may not succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures. Because of the inherent limitation of a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

PART II – OTHER INFORMATION

ITEM 1 Legal Proceedings

We are engaged from time to time in the defense of lawsuits arising out of the ordinary course and conduct of our business. We believe that the outcome of our current litigation will not have a material adverse impact on our business, financial condition and results of operations. However, we could be subsequently named as a defendant in other lawsuits that could adversely affect us.

ITEM 1A Risk Factors

The following is an update to a risk factor described in our annual report on Form 10-K for the year ended December 31, 2012, as amended, and should be read in conjunction with the other risk factors therein. The risks described below and in our Form 10-K, as amended, are not the only risks facing our Company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results.

Changes in the method or rates of third-party reimbursement could have a negative impact on our results.

From time to time, changes designed to contain healthcare costs have been implemented, some of which have resulted in decreased reimbursement rates for diagnostic imaging services that impact our business. For services for which we bill Medicare directly, we are paid under the Medicare Physician Fee Schedule, which is updated on an annual basis. Under the Medicare statutory formula, payments under the Physician Fee Schedule would have decreased for the past several years if Congress failed to intervene.

Medicare program reimbursements for physician services as well as other services to Medicare beneficiaries who are not enrolled in Medicare Advantage plans are based upon the fee-for-service rates set forth in the Medicare Physician Fee Schedule, which relies, in part, on a target-setting formula system called the SGR. Each year, on January 1st, the Medicare program updates the Medicare Physician Fee Schedule reimbursement rates. Many private payors use the Medicare Physician Fee Schedule to determine their own reimbursement rates. Based on the SGR, the annual fee schedule update is adjusted to reflect the comparison of actual expenditures to target expenditures. Because one of the factors for calculating the SGR is linked to the growth in the U.S. gross domestic product (“GDP”), the SGR formula may result in a negative payment update if growth in Medicare beneficiaries’ use of services exceeds GDP growth, a situation which has occurred every year since 2002 and the reoccurrence of which we cannot predict.

CMS determined that, effective January 1, 2013, the SGR formula results in a decrease to the physician Medicare fee schedule reimbursement by 26.5%. Congress, however, enacted ATRA which provides, in part, that Medicare physician fee schedule rates for 2012 are extended through December 31, 2013. Therefore, the Medicare fee schedule rates for 2013 are neither subject to the 26.5% SGR formula-driven reduction nor are they subject to any increase over and above the 2012 fee schedule rates.

While Congress has repeatedly intervened to mitigate the negative reimbursement impact associated with the SGR formula, there is no guarantee that Congress will continue to do so in the future. Moreover, the existing methodology may result in significant yearly fluctuations in the Medicare Physician Fee Schedule amounts, which may be unrelated to changes in the actual costs of providing physician services. Unless Congress enacts a change to the SGR methodology, the uncertainty regarding reimbursement rates and fluctuation will continue to exist. Moreover, if Congress does change the SGR methodology or substitute a new system for physician fee-for-service payments, it may require reductions in other Medicare programs including Medicare Advantage to offset such additional costs.

On April 1, 2013, CMS published its Contract Year 2014 Final Call Letter. In the Final Call Letter, CMS made the assumption that Congressional action would be taken to prospectively fix the Medicare physician fee schedule's sustainable growth rate formula and that there would be a 0% change in the Medicare physician fee schedule rates for 2014. Based on these assumptions, CMS estimated a 3.3% increase in the 2014 Medicare Advantage rates. An increase in the 2014 Medicare Advantage rates would increase our revenues derived from services rendered by Medicare Advantage enrollees. However, we cannot predict how future Congressional action relating to the SGR formula will impact our revenues and there continues to be a risk that Congress will be unable to resolve the SGR formula's automatic rate reductions which could subsequently reduce Medicare Advantage plan payments and could have a negative impact on our revenues.

Another provision that affects physician payments under the Medicare Physician Fee Schedule is an adjustment under the Medicare statute to reflect the geographic variation in the cost of delivering physician services, by comparing those costs to the national average. Medicare payments to physicians under the Medicare Physician Fee Schedule are geographically adjusted to reflect the varying cost of delivering physician services across areas. The adjustments are made by indices, known as the Geographic Practice Cost Indices ("GPCI") that reflect how each geographic area compares to the national average. In 2003, Congress established that for three years there would be a floor of 1.0 on the work component of the Medicare Physician Fee Schedule formula used to determine physician payments, which meant that physician payments would not be reduced in a geographic area just because the relative cost of physician work in that area fell below the national average. Congress extended the GPCI work floor several times since its enactment in 2003. ATRA provides another extension through December 31, 2013. Although Congress has extended the GPCI work floor several times, there is no guarantee that Congress will block the adjustment in the future, which could result in a decrease in payments for physician services.

The 2013 Medicare Physician Fee Schedule also expanded a reduction in reimbursement for multiple images on contiguous body parts to new services, namely diagnostic cardiovascular services and ophthalmology services. Medicare has a longstanding policy to reduce payment by 50% for the second and subsequent procedures furnished to the same beneficiary by a single physician or physicians in the same group practice on the same day, largely based on the presence of efficiencies in the practice expense and physician work. This policy already applies to the technical and professional component of advanced imaging services. Under the new expansion CMS shall apply a 25% reduction to the technical component of second and subsequent diagnostic cardiovascular services, and a 20% reduction to the technical component of second and subsequent diagnostic ophthalmology services, furnished by the same physician (or physicians in the same group practice) to the same beneficiary, on the same day. This further reduces payments for physician services relating to diagnostic imaging, and our associated revenues. Regulatory updates to payment rates for which we bill the Medicare program directly are published annually by CMS in the Federal Register. Current payment rates for certain diagnostic services using equipment costing more than \$1 million are subject to usage assumptions at a usage rate of 75%. However, as part of ATRA, Congress paid for part of the SGR freeze by increasing the equipment utilization threshold for advanced imaging modalities from the current 75% to 90% beginning January 2014.

ITEM 2 Unregistered Sales of Equity Securities and Use of Proceeds

None

ITEM 3 Defaults Upon Senior Securities

None

ITEM 4 Mine Safety Disclosures

Not applicable.

ITEM 5 Other Information

None

ITEM 6 Exhibits

Reference is made to the Exhibit Index included herein.

40

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

RADNET, INC.

(Registrant)

Date: May 10, 2013 By: /s/ Howard G. Berger, M.D.
Howard G. Berger, M.D., President and
Chief Executive Officer

(Principal Executive Officer)

Date: May 10, 2013 By: /s/ Mark D. Stolper
Mark D. Stolper, Chief Financial Officer
(Principal Financial and Accounting Officer)

INDEX TO EXHIBITS

<u>Exhibit Number</u>	<u>Description</u>
31.1	Certification of Howard G. Berger, M.D. pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2	Certification of Mark D. Stolper pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1	Certification Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of The Sarbanes-Oxley Act of 2002 of Howard G. Berger, M.D.
32.2	Certification Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of The Sarbanes-Oxley Act of 2002 of Mark D. Stolper.
101.INS**	XBRL Instance Document
101.SCH**	XBRL Schema Document
101.CAL**	XBRL Calculation Linkbase Document
101.LAB**	XBRL Label Linkbase Document
101.PRE**	XBRL Presentation Linkbase Document
101.DEF**	XBRL Definition Linkbase Document

Pursuant to Rule 406T of Regulation S-T, the Incentive Data Files on Exhibit 101 hereto are deemed not filed or **part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as deemed not filed for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, and otherwise are not subject to liability under those sections.